PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	**FOR FURTHER ACTION** see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No.	International filing date *(day/month/year)*	(Earliest) Priority Date *(day/month/year)*
PCT/GB 98/03397	12/11/1998	12/11/1997
Applicant		
NATIONAL ENVIRONMENTAL RESEARCH COUNCIL et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.

[X] It is also accompanied by a copy of each prior art document cited in this report.

1. **Basis of the report**

   a. With regard to the **language,** the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

   [ ] the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

   b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

   [X] contained in the international application in written form.

   [ ] filed together with the international application in computer readable form.

   [X] furnished subsequently to this Authority in written form.

   [ ] furnished subsequently to this Authority in computer readble form.

   [ ] the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

   [ ] the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. [X] **Certain claims were found unsearchable** (See Box I).

3. [ ] **Unity of invention is lacking** (see Box II).

4. With regard to the **title,**

   [ ] the text is approved as submitted by the applicant.

   [X] the text has been established by this Authority to read as follows:

   TISSUE CEMENT PROTEINS FROM RHIPICEPHALUS APPENDICULATUS

5. With regard to the **abstract,**

   [X] the text is approved as submitted by the applicant.

   [ ] the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No. _____

   [ ] as suggested by the applicant.

   [ ] because the applicant failed to suggest a figure.

   [ ] because this figure better characterizes the invention.

   [X] None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 98/03397

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 28, 29 and 24, 26 (as far as in vivo methods are concerned) are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No
[redacted]/GB 98/03397

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/12 C12N15/86 C12N15/62 C12N5/10 C07K14/435
A61K38/17 A61K39/00 A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N C07K A61K A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	A.L. CRAMPTON ET AL.: "Expression sequenced tags and new genes from the cattle tick, Boophilus microplus" EMBL SEQUENCE DTABASE,11 September 1997, XP002093748 Heidelberg, FRG Boophilus microplus EST 198 putative nuclear antigen mRNA sequence; Accession no. U92768; & EXP. APPL. ACAROL. , vol. 22, no. 3, 1998, pages 177-186, --- -/--	1

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
19 February 1999	05/03/1999

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Hornig, H

2

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
A	D.C. JAWORSKI ET AL.: "Tick (Acari: Ixodidae) attachement cement and salvary gland cells contain similar immunoreactive polypeptides" JOURNAL OF MEDICAL ENTOMOLOGY, vol. 29, no. 2, March 1992, pages 305-309, XP002093749 Published by The Entomological Society of America, Lanham, Maryland, US cited in the application see the whole document ---	1-40
A	D.C. JAWORSKI ET AL.: "Evidence that a 90 kDa tick salivary galnd polypeptide is a cement protein" F.DUSBÁBEK AND V. BUKVA (EDS.): MODERN ACAROLOGY, ACADEMIA PRAGUE, vol. 1, 1991, pages 335-340, XP002094114 SPB Academic Publishing bv, The Hague, NL Modern Acarology Volume I. Proceedings of the VIII International Congress of Acarology, Held in Ceske Budejovice, Czechoslovakia, 6-11 August 1990; see the whole document ---	1-40
A	S. SHAPIRO ET AL.: "Acquired resistance to Ixodid Ticks induced by Tixk cement antigen" EXPERIMENTAL & APPLIED ACAROLOGY, vol. 7, 1989, pages 33-41, XP002093750 Elsevier Science Publishers B.V., Amsterdam, NL cited in the application see the whole document ---	1-40
A	S.Z. SHAPIRO ET AL.: "Tick antigens recognized by serum from a guinea pig resistant to infestation with the tick Rhipicephalus appendiculatus" J. PARASITOLOGY, vol. 72, no. 3, June 1986, pages 454-463, XP002093751 see the whole document ---	1-40
A	WANG H ET AL: "COMPARISON OF THE PROTEINS IN SALIVARY GLANDS, SALIVA AND HAEMOLYMPH OF RHIPICEPHALUS APPENDICULATUS FEMALE TICKS DURING FEEDING" PARASITOLOGY, vol. 109, no. 4, November 1994, pages 517-523, XP002050816 see the whole document --- -/--	1-40

2

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
A	S.J. BROWN AND P.W. ASKENASE: "Amblyomma americanum: Physicochemical Isolation of a protein derived from the ick slivary gland that is capable of inducing immune resistance in guinea pigs" EXPERIMENTAL PARASITOLOGY, vol. 62, no. 1, August 1986, pages 40-50, XP002093752 NEW YORK, US cited in the application see the whole document ---	1-40
A	G.R. NEEDHAM ET AL.: "Characterization of Ixodid Tick salivary-gland gene products, using recombinant DNA technology" EXPERIMENTAL & APPLIED ACAROLOGY, vol. 7, 1989, pages 21-32, XP002093753 Elsevier Science Publishers, B.V., Amsterdam, NL cited in the application see the whole document ---	1-40
A	GB 2 142 334 A (INT CENTRE OF INSECT PHYSIOLOG) 16 January 1985 see the whole document -----	1-40

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
GB 98/03397

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2142334 A	16-01-1985	NONE	

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

TISSUE CEMENT PROTEINS FROM RHIPICEPHALUS APPENDICULATUS

The present invention relates to tissue cement proteins produced by certain species of blood-feeding ectoparasites. These proteins and compositions comprising these proteins are particularly useful for the temporary or permanent bonding of animal tissues to each other or to other biomaterials. The present invention also relates to the use of tissue cement proteins in the production of vaccines that protect animals against the bite of blood-sucking ectoparasites and the transmission of viruses, bacteria and other pathogens by such ectoparasites.

Cement is produced by many blood-feeding ectoparasites, including certain species of Ixodid ticks. Ixodid (hard) ticks are haematophagous parasites that attach themselves to a vertebrate host by means of a 'cement cone', a product of the type II and type III acini of the tick salivary glands (Kemp *et al.*, 1982; Walker *et al.*, 1985). (All documents referred to herein are listed at the end of the description.)

The cement that forms the cone is a milky-white secretion that is injected into the skin of animals on which these parasites feed. The cement comprises a number of interacting protein and carbohydrate components. The cement spreads into the bite site and over the skin and, upon hardening, ensures that the mouthparts remain firmly anchored to the host during the feeding period, which typically lasts 4 to 8 days. The cement cone functions additionally as a gasket to prevent leakage of fluids from the bite site during feeding.

The tick cement cone is a layered structure, constructed from two major types of cement. The first type of cement is produced just minutes after establishing the bite site and hardens quickly to form a rigid 'core' of the cone. A second type of cement is secreted later, about 24 hours after attachment, and hardens more slowly to form a more flexible 'cortex'. In adult ticks, cement production typically continues until the 3rd or 4th day after attachment (Kemp *et al.*, 1982; Sonenshine *et al.*, 1991).

The tick cement cone appears to be mainly proteinaceous, but also contains some carbohydrate and lipid. An early study found the amino-acid composition of whole cement in *Boophilus microplus* to be rich in glycine, leucine, serine and tyrosine (Kemp *et al.*, 1982). However, the individual proteins comprising the tick cement are very poorly characterised. Although the mobility of the component proteins has been shown on SDS-PAGE gels, none have yet been purified.

The process by which the cement components harden is also not understood, although mechanisms similar to the tanning of cuticle and coagulation of haemolymph have been proposed (Kemp *et al.*, 1982; Moorhouse and Tatchell, 1966). At present no direct scientific evidence has been produced to substantiate these theoretical mechanisms.

It has been noted that the polypeptides that form the cement cortex appear to be similar to certain structural components of vertebrate skin. Involvement of these vertebrate-like molecules may enable ticks to use host-derived enzymes during the cement hardening process, for example: lysyl oxidases which cross-link collagen and elastin (Siegel, 1979); or transglutaminases, such as the coagulation factor XIIIa, which is induced during wound healing and cross-links fibronectin, fibrins and collagen (Ichinose *et al.*, 1990). These enzymes may cross-link cortex polypeptides to the extracellular matrix proteins of the skin.

Other enzymes such as phenoloxidases or peroxidases which catalyse the hardening of arthropod extracellular structures (Sugumaran *et al.*, 1992) have been identified in *R. appendiculatus* salivary glands and are therefore likely to play a role in solidifying the cement cone.

The composition of tick cement appears to be similar amongst different Ixodid tick species. For example, an antiserum raised against a 90kD salivary protein of the brown ear tick, *Rhipicephalus appendiculatus*, has been shown to recognise polypeptides from the salivary glands and cement proteins of the American dog tick, *Dermacenter variabilis*, the lone star tick, *Amblyomma americanum*, and the brown

dog tick, *R. sanguineus* (Jaworski *et al.*, 1992).

All these tick species are extremely effective as transmitters of disease. For example, *R. appendiculatus* represents a major obstacle to livestock development in several sub-saharan regions. It transmits the protozoan parasite *Theileria parva* which causes the usually fatal East Coast Fever. This disease is often considered the most important disease of cattle (Norval *et al.*, 1992a; Norval *et al.*, 1992b). This tick is also the main vector of the virus causing Nairobi sheep disease, a disabling and often deadly disease in sheep and goats (Davies, 1988). *R. appendiculatus* and other tick pests also cause considerable damage to the skin, thereby affecting the leather industry.

In an effort to combat parasite-transmitted diseases, unpurified cement components have been tested as inducers of host resistance (Brown *et al.*, 1986; Shapiro *et al.*, 1989), but reliable vaccines based on cement proteins have not been successfully developed. Cone proteins would appear to be a reasonable target for a vaccine since the formation of the cone is essential for the tick to attach to the host and feed. However, only some of the cone proteins are antigenic.

There therefore exists a great need for an effective vaccine to combat diseases that are transmitted by blood-feeding ectoparasites. The elucidation of the components of tissue cement produced by these organisms would allow the rational design of such vaccines.

Furthermore, these molecules would prove useful in medicine as components of tissue cement. Presently available tissue cements are of two types, both of which suffer from significant disadvantages. Acrylic-based glues are extremely strong, yet are also very toxic and can thus only be used in very small quantities in the body. The second type of tissue cement used is non-immunogenic but forms a much less strong bond. Consequently this type of cement is only useful in a small number of surgical procedures. There is thus a great need for a non-immunogenic tissue cement that is capable of bonding mammalian tissue with great strength.

Summary of the invention

According to the present invention there is provided a tissue cement protein having the amino acid sequence shown in Figure 3 or Figure 7 or containing any one of the partial amino acid sequences shown in any one of Figures 2, 4 to 6 and 8, related tissue cement proteins from blood-feeding parasites, preferably ticks, and functional equivalents thereof.

The proteins of the present invention are of two subtypes: group A and group B. Proteins in group A form the cement cone core when secreted in saliva and harden quickly to form a rigid latex-like structure. The proteins in group B form the cortex of the cement cone and harden more slowly. The resulting structure is more flexible. Accordingly, functional equivalents of proteins of either group A or group B will possess these respective activities and properties.

The term "functional equivalents" is used herein to describe those proteins that have an analogous function to tissue cement proteins containing the amino acid sequences identified in any one of Figures 2 to 8.

These proteins may belong to the same protein family as the proteins and partial proteins identified in Figures 2 to 8. By protein family is meant a group of polypeptides that share a common function and exhibit common sequence homology between motifs present in the polypeptide sequences.

By sequence homology is meant that the polypeptide sequences are related by divergence from a common ancestor. In particular, as is discussed in more detail below, the proteins and partial proteins identified herein possess certain sequences in common that are repeated several times throughout the sequence of the protein. Preferably, the homology between polypeptide sequences is at least 50% across the whole of the amino acid sequence of the protein. More preferably, the homology is at least 75% across the whole of the amino acid sequence of the protein. Most preferably, homology is greater than 80% across the whole of the protein sequence.

By "analogous function" is meant firstly that the proteins have retained the capacity to form a cement. Such proteins will thus be capable of hardening over a period of time to form a solid mass or glue. Secondly, this term may refer to proteins that are structurally similar to group A or group B proteins and thus contain similar or identical epitopes. These functional equivalents may thus be used as immunogens to develop vaccines, directed against blood-feeding parasites, that target members of the tissue cement protein family.

Functional equivalents of tissue cement proteins may include, for example, mutants containing amino acid substitutions, insertions or deletions from the wild type sequence. Functional equivalents with improved function from that of the wild type sequence may also be designed through the systematic or directed mutation of specific residues in the protein sequence. Improvements in function that may be desired will include greater strength of bonding, faster speed of bonding or greater flexibility of the hardened cement.

Functional equivalents of tissue cement proteins or protein fragments may be made more or less immunogenic than the corresponding wild type protein or protein fragment in order to suit a desired application. If the proteins are to be used in surgical procedures as tissue cements then the proteins should ideally be non-immunogenic to evade attack by the immune system. However, if the tissue cement proteins are to be used in a vaccination regime to induce host resistance to parasite proteins, then the proteins may be modified so as to enhance their immunogenicity. They will thus be more likely to elicit an immune response in the vaccinated host.

Functional equivalents will include conservative amino acid substitutions that do not affect the function or activity of the protein in an adverse manner. This term is also intended to include natural biological variants (e.g. allelic variants or geographical variations within the species from which the tissue cement proteins are derived).

According to the invention, fragments of tissue cement proteins are also envisioned as functional equivalents. Fragments that have retained those portions of the protein that are responsible for a desired activity may prove ideal in certain applications. For example, short stretches of peptide derived from immunogenic portions of tissue cement proteins will be useful as immunogens. An antibody will normally recognise an epitope comprising between six and twelve amino acid residues. Such short stretches of polypeptide sequence are simple to produce in large quantities, either synthetically or through recombinant means.

The tissue cement proteins of the present invention may function either as a structural component of tissue cement or may possess an enzymatic activity directed against the structural components of the tissue cement.

It is thought that most of the protein and partial protein sequences so far identified and shown in Figures 2 to 8 are structural components of tissue cement. The applicant, however, does not wish to be bound by this theory. For example, the protein sequence identified in Figure 2 appears to contain a signal sequence and its sequence resembles that of keratin, a widely studied structural protein. Similarly, the protein whose sequence is set out in Figure 3 also contains a signal sequence and is glycine and proline rich, like many structural proteins. The cemA protein, whose partial sequence is illustrated in Figure 4, contains a number of repeats and is thus also likely to be a structural component of tissue cement.

The protein of Figure 5 is composed of a number of repeats and resembles collagen in sequence. The encoding cDNA shares sequences in common with glutenin, a known self-assembling protein. It thus seems likely that this protein is capable of self-assembly. The applicant, however, does not wish to be bound by this theory. The possibility that this particular sequence may be involved in self-assembly raises the opportunity of using these motifs to bestow on an unrelated protein the ability to self-assemble.

In common with some of the other proteins illustrated in the accompanying Figures, the protein of Figure 6 contains a number of consensus recognition sites for carbohydrate moieties, in particular glycosaminoglycans.

The protein sequence illustrated in Figure 7 also contains consensus attachment sites for glycosaminoglycan moieties and possesses a putative signal sequence. The amino terminal half of the protein resembles collagen, whilst the carboxy terminal shares more in common with keratin. The protein is glycine-rich and contains several repeats of the motif (C/S)1-4(Y/F) which is also found in structural proteins from the egg shells of certain insects. The tyrosines in these consensus sequences may be involved in the cross-linking of this protein through the formation of dityrosine bridges by the action of phenoloxidases.

The sequence of Figure 8 is both glycine and tyrosine rich and resembles a cement protein of the reef-building polychaete *Pragmatopoma californica* (see Figure 9). It is thus likely that this protein is also a structural component of tissue cement. The applicant, however, does not wish to be bound by this theory.

The enzymatic activity that may be possessed by the tissue cement proteins of the present invention may involve the ability to effect such covalent modifications as phosphorylation, glycosylation, reduction or oxidation of other proteins and carbohydrate moieties and may result in the cross-linking of the structural components of the tissue cement. Cross-linking may be either reversible or irreversible and may occur between homologous or heterologous components of the tissue cement. The cross-linking may also occur between tissue cement proteins and non-parasite proteins such as, for example, components of vertebrate tissue.

The tissue cement proteins of the present invention may be group A proteins. By "group A" is meant that in parasite saliva these proteins form the core of the cement cone. The function of the cone core in parasites is to attach to the skin of a vertebrate host and to form a rigid bond that will not break easily. Accordingly, these proteins form a hard latex-like cement that sets and bonds to the vertebrate skin quickly. Group

A proteins are thus ideally suited to applications that require a quick-setting tough bond.

The tissue cement proteins of the present invention may be group B proteins. By "group B" is meant that in tick saliva these proteins form the cortex of the cement cone. One function of the cortex in parasites is to form a gasket-like seal around the bite site, to prevent leakage of fluids. A further function of the cortex proteins is to form a flexible hinge so that the parasite will not be easily brushed off its host. Accordingly, group B proteins harden more slowly than group A proteins, but set to form a more flexible, pliant cement. These proteins are thus ideally suited for applications when a more flexible bond is required.

Many of the structural tissue cement proteins of the present invention share in common the ability to bind to vertebrate tissue. This binding may be due to an inherent affinity possessed by the protein for certain components of the vertebrate skin, such as collagen. However, an affinity for vertebrate proteins may only manifest itself when in the presence of enzymes whose activity is required in order to generate an association between a tissue cement protein and a component of the skin. This enzymatic activity may be derived from tissue cement proteins themselves or may be provided by enzyme components of the vertebrate skin, such as lysyl oxidases, that cross-link collagen and elastin or transglutaminases, such as the coagulation factor XIIIa, that cross-link fibronectin, fibrins and collagen during many vertebrate healing processes.

The tissue cement proteins or their functional equivalents according to the present invention may be derived from any blood-feeding parasite. Preferably, the tissue cement proteins of the present invention are derived from blood-feeding ectoparasites, more preferably ticks. Most preferably, the tissue cement proteins of the present invention are derived from the brown ear tick *Rhipicephalus appendiculatus*.

The tissue cement proteins of the present invention may also comprise carbohydrate components. Many tissue cement proteins are in fact glycoproteins, containing carbohydrate attachments covalently bound at various sites in the protein. The

carbohydrate generally will comprise a series of monosaccharide units that commonly occur as an oligosaccharide or fairly small polysaccharide. As has been discussed briefly above, many of the proteins so far identified in ticks possess consensus attachment sites for glycosaminoglycans (glycans containing aminosaccharide residues).

The tissue cement proteins of the invention may be present in the tissue cement as monomers, dimers, tetramers, or as oligomers comprising a number of homologous or heterologous monomers as one unit. This is particularly true of structural tissue cement proteins, which may associate non-covalently as part of the cement hardening process. The applicant, however, does not wish to be bound by this theory.

The tissue cement proteins of the present invention may be purified from cement produced by live parasites. This may be done by treating collected cones with a wash solution such as PBS, a TRIS buffer or non-ionic detergents, for example Tween-20 or Triton. Cement proteins may be prepared through immunoprecipitation using antibodies that are specific for epitopes in the protein sequence. Alternatively, the proteins may be prepared synthetically, or using techniques of genetic engineering. Preferably, the tissue cement proteins of the present invention comprise recombinant polypeptides produced by expression from an encoding nucleic acid.

Synthetic molecules designed to mimic the tertiary structure or active site of the tissue cement proteins constitute a further aspect of the invention.

A further aspect of the present invention comprises tissue cement proteins that are fused to other molecules such as labels, toxins or bioactive molecules. Particularly suitable candidates for fusion will be reporter molecules such as luciferase, green fluorescent protein or horse radish peroxidase. Linker molecules such as streptavidin or biotin may also be used. Additionally, bioactive peptides or polypeptides may be fused to a tissue cement protein. Such molecules may comprise molecules with antiseptic or antibiotic properties, or toxins for targeting to cancer cells.

The proteins may be fused chemically, using methods such as chemical cross-linking. Such methods will be well known to those of skill in the art and may comprise, for example, cross-linking of the thiol groups of cysteine residues. Chemical cross-linking will in most instances be used to fuse tissue cement proteins to non-protein molecules, such as labels. The labels may be radiolabels or labels that can be detected spectroscopically, for example fluorescent or phosphorescent chemical groups.

When it is desired to fuse a tissue cement protein to another protein molecule, the method of choice will often be to fuse the molecules genetically. In order to generate a recombinant fusion protein, the genes or gene portions that encode the proteins or protein fragments of interest are engineered so as to form one contiguous gene arranged so that the codons of the two gene sequences are transcribed in frame.

A tissue cement protein may be fused genetically to any protein for which the encoding gene sequence is or becomes known. Particularly suitable candidates for fusion will be reporter molecules such as luciferase, green fluorescent protein, biotin, avidin, streptavidin or horse radish peroxidase. Additionally, toxin peptides or polypeptides may be fused to a tissue cement protein. Antiseptic or antibiotic proteins and peptides may also be fused to the tissue cement proteins of the present invention.

According to a further aspect of the present invention there is provided a pharmaceutical composition comprising a tissue cement comprising a mixture of group A and group B tissue cement proteins in the absence of other parasite saliva proteins, optionally in the presence of one or more compounds capable of cross-linking said tissue cement proteins, in conjunction with a pharmaceutically-acceptable excipient.

Such a pharmaceutical composition has many applications, particularly in skin surgery and wound healing, for the temporary or permanent bonding of human or animal tissues to each other or to other biomaterials.

Tissue cement has previously been used in surgical procedures to provide adhesion and stability to living tissues to enable the normal processes of healing and repair to take place or to provide a long term bond in situations where normal healing is delayed or unlikely to occur. Tissue cement formed from the proteins of the present invention have several advantages over conventional tissue cements. For example, the proteins of the invention form strong bonds with vertebrate tissues. This makes them ideal for use as components of a tissue cement to bond two tissue surfaces or edges together.

Different surgical procedures necessitate the use of tissue cement with different properties. Tissue cement formed from the proteins of the present invention is therefore ideal, since the hardening or elastic properties of the cement may be tailored precisely to provide the particular requirements of the surgical procedure through modification of the relative amounts of group A and group B proteins that the cement comprises. The tissue cement is in this manner extremely versatile.

Tissue cement with a high content of group A proteins will generally be useful for procedures that require an extremely tough bond that will not need to flex to any great extent. A good example of such a bond might be a bond between two bone surfaces or between a bone surface and the surface of an artificial joint. A high group A content tissue cement will also be required when it is necessary that the bond sets quickly.

For procedures such as the bonding of skin lacerations, where a high degree of flexibility is required, a tissue cement will be used that contains a high content of group B proteins. However, group B proteins do bond more slowly, so tissue cement with a high group B content will not generally be used for procedures that require a tough bond to form rapidly. However, this cement may be used in conjunction with other measures, such as surgical staples or group A tissue cement, that can form a quick bond to hold the tissues together while the group B proteins harden.

Pharmaceutical compositions that comprise tissue cement proteins according to the present invention may also contain additional preservatives, or components responsible for the prevention of premature setting. The composition may also

comprise a propellant, for instance, if the tissue cement is to be sprayed onto tissue surfaces. Such compounds will be well known to those of skill in the art.

One important advantage of the tissue cement proteins of the present invention is that, *in situ* in vertebrate tissue these proteins are non-immunogenic and therefore do not cause inflammation of the tissue. This is particularly relevant when the tissue cement is intended for internal use, for example in the securing of prolapsed organs. Were the tissue cement immunogenic, an immune attack would be directed against the tissue cement, so causing local inflammation, disrupting the cement and preventing the permanent bonding of the tissue.

The current rationale in surgery to overcome immune rejection involves combatting the initial rejection phenomena until, eventually, the immune system becomes tolerant. For example, after organ transplants, huge combined doses of immunosuppressive agents are initially required that are gradually reduced during treatment until, if the transplant successfully survives for a year or so, very little maintenance immunotherapy is required.

The tissue cement proteins of the present invention can also be used to prevent immune rejection. Aside from their natural non-immunogenicity, another property of the tissue cement proteins of the present invention is that the proteins themselves bind to bioactive proteins in the saliva of an ectoparasite, such as tick histamine-binding proteins. By doing this, the cement proteins localise the action of the various immunosuppressive molecules produced by the organism. These immunosuppressive compounds alter over time during the course of feeding in order to adapt to the host's rejection response. Hence the cement cone, in effect, is an active local immunosuppressive structure.

The ability to bind to bioactive parasite proteins means that tissue cement comprising tissue cement proteins according to the present invention may be complemented with certain immunosuppressive molecules produced by some parasites. For example, suitable molecules might include vasoactive amine binding molecules that are the

subject of co-pending International patent application PCT/GB97/01372. These molecules will bind to the tissue cement, and so provide a local immunosuppressive structure that will disguise any allogeneic or even xenogeneic organ and prevent its rejection.

These properties of the tissue cement proteins of the present invention thus provide an addition to the conventional uses of tissue cement to hold articulated joints to bone or to repair damaged organs. Aside from its use as a non-immunogenic adhesive, tissue cement produced according to the present invention may be used as an adjunct to organ transplantation to supply and localise immunosuppressive compounds to the locality of the transplant.

A further aspect of the present invention is therefore to provide tissue cement with immunosuppressive properties by complementation of the basic cement with one or more tissue cement proteins of the present invention, optionally in conjunction with parasite-derived immunosuppressive compounds.

Other specific applications of tissue cement formed from the tissue cement proteins of the present invention may include, but will not be confined to, those given in the following list:

repair of incised surgical wounds in place of conventional closures such as sutures or staples; repair of lacerations such as perineal tears following childbirth or flap lacerations after trauma; the grafting of skin, cultured skin substitutes or biomaterial substitutes to chronic wounds, burns, skin graft donor sites and in reconstructive or cosmetic plastic surgery; the securing of myoplastic flaps; tissue to tissue repair such as repair of lacerations of the liver or other parenchymatous organs; tissue to tissue anastomosis such as gastrointestinal anastomosis or tissue to biomaterial anastomosis such as vascular repair or anastomosis; tissue to tissue reconstruction such as the securing of prolapsed organs in their anatomical site; tissue to tissue approximation as in pleuro-pleural adhesion following recurrent pneumothorax; as a sclerosant in procedures such as the injection of haemorrhoids; in neurosurgical procedures such as the repair or patching of dura mater with natural or artificial substitutes and the

grafting or repair of severed neural tissue; in orthodontic procedures such as the re-implantation of teeth or the reconstruction of the mandibular or maxillary arches using bone chips or materials such as collagen matrices or hydroxyapatite; in orthopaedic procedures including vertebral fusion, arthrodesis, fixation of fractions and osteotomies and the implantation of prostheses such as hip arthroplasty; in procedures such as rhytidectomy where the use of sutures is undesirable on cosmetic grounds; securing of artificial materials such as Marlex™ mesh in hernioplasty (performed in open operation or endoscopically); repair of friable tissue such as tendon or muscle; as a haemostat on oozing surfaces or in circumstances where haemostasis by conventional means is difficult to secure (for example during endoscopic surgery); for the obliteration of sinuses and fistulae; and for sealing perforations of hollow visci such as the stomach or duodenum (either used alone or in conjunction with a tissue or artificial patch.

In a still further embodiment of the invention, the use of tissue cement proteins is provided as tools in the study of cement cone assembly and in the development of strategies to prevent cement cone assembly, and thereby inhibit tick attachment and feeding. For example, monoclonal antibodies and engineered vaccines directed against tissue cement proteins could be used to prevent parasite feeding.

Arthropod parasites are sources of infectious disease agents such as tick-borne encephalitis virus, Crimean-Congo haemorrhagic fever virus, Nairobi sheep virus, *Borrelia burgdorferi* (the agent of lyme disease), *Theileria parva* (the agent of East Coast fever) and other injurious effects that have major impacts in human and veterinary medicine. Control of the arthropod parasites currently relies primarily on the use of chemicals such as acaricides.

Attempts have been made to use immunological means of control through vaccine technology. Some success has been met in identifying certain protective antigens of arthropod parasites as being potential vaccine candidates, but only a few have as yet come to commercial fruition, most notably for the cattle tick *Boophilus microplus*. Despite these developments, there is nonetheless a continuing need for arthropod

parasite vaccines and in particular for a vaccine which may be used against ticks.

An alternative vaccine strategy that has until now not been possible is to vaccinate animals using purified antigens. The immune system of the animal thus develops an improved humoral response to these antigenic polypeptides and correspondingly develops resistance against the arthropod parasites themselves.

One disadvantage of using vaccines directed against a specific vector-transmitted disease to control that disease is that a different vaccine is usually required to protect against each disease. Vaccines directed against disease vectors (such as ticks and mosquitoes) have an added advantage in that their effect may control several different infections, as long as these infections are transmitted by only one type of disease vector.

The present invention therefore also provides for the use of tissue cement proteins as defined above as immunogens. Accordingly, a further aspect of the present invention comprises a vaccine comprising one or more tissue cement proteins as defined above in an arthropod parasite vaccine and in particular as protective immunogens in the control of diseases caused by infections transmitted by arthropod parasites.

The vaccine may be administered singly, or in combination with other immunogens. The vaccine may include adjuvants of the type which are well known in the art, for example, alum. Suitable candidates for vaccination include humans and domesticated animals such as cattle, goats, sheep, dogs, cats and other mammalia. All these species require protection against arthropod parasites, particularly ticks, and the infections they transmit.

According to a further aspect of the present invention there is provided a nucleic acid molecule encoding a tissue cement protein as defined above, or any functionally equivalent form. The nucleic acid sequences of choice comprise or contain the nucleic acid sequences exhibited in Figures 2 to 8. The skilled man will appreciate that changes may be made at the nucleotide level by addition, substitution, deletion or

insertion of one or more nucleotides, which changes may or may not be reflected at the amino acid level, dependent on the degeneracy of the genetic code.

The nucleic acid molecule according to this aspect of the present invention may comprise DNA, RNA or cDNA and may additionally comprise nucleotide analogues in its sequence. Preferably, the nucleic acid comprises DNA, more preferably single or double-stranded cDNA.

Antisense sequences may also be designed with respect to the nucleic acids of this aspect of the invention and in sequence will in whole or in part comprise that of the complementary strand to the coding nucleic acid strand. Oligonucleotides comprising antisense sequences to tissue cement protein genes may be used as diagnostic tools in the detection of organisms or vectors expressing nucleic acids that encode tissue cement proteins. These single-stranded oligonucleotides will comprise lengths of nucleic acid of between 10 and 300 nucleotides, preferably between 10 and 100 nucleotides, most preferably of between 10 and 30 nucleotides. The oligonucleotides may be labelled in order to aid their detection. Suitable labelling systems are well known in the art.

Methods for screening cDNA libraries for proteins analogous to the tissue cement proteins described herein will be apparent to the man of skill in the art. The antisense sequences of this aspect of the invention therefore may not correspond exactly to the complementary strand of the nucleic acid that encodes a tissue cement protein. For example, when using antisense oligonucleotides as probes in the screening of a cDNA library for proteins analogous to the tissue cement proteins described herein, due to the degeneracy of the genetic code and inter-species sequence divergence, any analogous genes to those described herein are likely to comprise sequences that are significantly different to that of the probe.

Accordingly, antisense sequences for use in accordance with this aspect of the present invention comprise sequences that hybridise under standard conditions to the nucleic acid sequences exhibited in Figures 2 to 8. 'Hybridising sequences' included within

the scope of the invention are those binding under standard conditions. As used herein, by 'standard conditions' is meant both non-stringent standard hybridisation conditions (6 x SSC/50% formamide at room temperature) with washing under conditions of low stringency (2 x, room temperature, or 2 x SSC, 42°C) or at standard conditions of higher stringency, e.g. 2 x SSC, 65°C (where SSC = 0.15M NaCl, 0.015M sodium citrate, pH 7.2). Preferably standard conditions refers to conditions of high stringency.

A further aspect of the present invention comprises a method of production of a tissue cement protein which method comprises expression from the encoding nucleic acid therefor. Expression may conveniently be achieved by culturing under appropriate conditions recombinant host cells containing the nucleic acid.

Systems for cloning and expression of a polypeptide in a variety of different host cells are well known. Suitable host cells include bacteria, mammalian cells, yeast and baculovirus systems. Mammalian cell lines available in the art for expression of a heterologous polypeptide include Chinese hamster ovary cells, HeLa cells, baby hamster kidney cells and many others. A common, preferred bacterial host is *E. coli*.

The expression of heterologous polypeptides and polypeptide fragments in prokaryotic cells such as *E. coli* is well established in the art; see for example *Molecular Cloning: a Laboratory Manual*: 2nd edition, Sambrook et al., 1989, Cold Spring Harbor Laboratory Press. Expression in eukaryotic cells in culture is also an option available to those skilled in the art for the production of heterologous proteins; see recent reviews, for example O'Reilly *et al.*, (1994), Baculovirus expression vectors - a laboratory manual, Oxford University Press.

Suitable vectors can be chosen or constructed for expression of tissue cement proteins, containing the appropriate regulatory sequences, including promoter sequences, terminator sequences, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate. Vectors may be plasmids, viral e.g. bacteriophage, or phagemid, as appropriate. For further details see *Molecular Cloning: a Laboratory Manual* (loc. cit). Many known techniques and protocols for manipulation of nucleic

acid, for example, in the preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in *Short Protocols in Molecular Biology*, Second Edition, Ausubel et al. eds., John Wiley & Sons, 1992. For example, in eukaryotic cells, the vectors of choice are virus-based, such as baculovirus-based.

A further aspect of the present invention provides a host cell containing a nucleic acid encoding a tissue cement protein or functional equivalent thereof. A still further aspect provides a method comprising introducing such nucleic acid into a host cell or organism. Introduction of nucleic acid may employ any available technique. In eukaryotic cells, suitable techniques may include calcium phosphate transfection, DEAE-Dextran-mediated transfection, electroporation, liposome-mediated transfection or transduction using retrovirus or other viruses, such as vaccinia or, for insect cells, baculovirus. In bacterial cells, suitable techniques may include calcium chloride transformation, electroporation or transfection using bacteriophage.

Introduction of the nucleic acid may be followed by causing or allowing expression from the nucleic acid, e.g. by culturing host cells under conditions for expression of the gene.

In one embodiment, the nucleic acid of the invention is integrated into the genome (e.g. chromosome) of the host cell. Integration may be promoted by inclusion of sequences which promote recombination with the genome, in accordance with standard techniques.

Transgenic animals transformed so as to express or overexpress in the germ line one or more tissue cement proteins or functional equivalents as described herein form a still further aspect of the invention, along with methods for their production. Many techniques now exist to introduce transgenes into the embryo or germ line of an organism, such as those illustrated in Watson *et al.*, (1994) Recombinant DNA (2nd edition), Scientific American Books.

Various aspects and embodiments of the present invention will now be described in more detail by way of example, with particular reference to tissue cement proteins isolated from ticks, and especially from *Rhipicephalus appendiculatus*. It will be appreciated that modification of detail may be made without departing from the scope of the invention.

Brief description of the Figures

Figure 1A is an SDS-gel containing male and female salivary gland extract (SGE) and male and female cement polypeptides obtained by rinsing cement cones in PBS.

Figure 1B is the corresponding Western blot to Figure 1A, probed with a polyclonal antiserum raised against a 17 Kd protein purified from tick salivary gland extract.

Figure 2 is a partial cDNA sequence and translation product of clone 21. The cDNA-inferred protein is a cement protein; it contains a hydrophobic N-terminal region which possibly constitutes a signal sequence, typical for secreted proteins. The protein strongly resembles other structural proteins, especially keratin. A recognition sequence for post-translational attachment of glycosaminoglycan groups is underlined.

Figure 3 is the cDNA and cDNA-inferred polypeptide sequence of clone 33. A putative signal sequence is given in bold. Like many structural proteins, this protein is glycine- and proline-rich. The protein also displays some resemblance to keratins.

Figure 4 is a partial sequence of *cemA* cDNA and the cDNA-inferred polypeptide sequence. The protein is very repetitive, with the sequence KGALLQQQQASQVKGALKAI, or slight variants thereof, repeated several times.

Figure 5 is a partial cDNA and cDNA-inferred polypeptide sequence of clone 24. The protein has resemblance to structural proteins (amongst others collagen), and is contains repeats. The cDNA also has a region in common with glutenin, a self-assembling protein.

Figure 6 is a partial cDNA and cDNA-inferred sequence of clone 68. The encoded proteins resemble structural proteins, such as keratin. A series of putative glycosaminoglycan attachment sites are underlined.

Figure 7 is the complete cDNA sequence and cDNA-inferred polypeptide sequence of clone 64. The putative signal sequence is give in bold. A possible glycosaminoglycan attachment site is underlined. The first 40 amino-acid section of the mature protein is collagen-like, whilst the remainder of the sequence resembles keratin. The protein is glycine-rich and contains several repeats of the motif (C/S)1-4(Y/F), which is also found in structural proteins from insect egg shells. The tyrosines may be involved in cross-linking by formation of dityrosine-bridges by phenoloxidases. A similar protein is encoded by clone I (see Figure 8).

Figure 8 is a partial cDNA-sequence and cDNA-inferred polypeptide sequence of clone I. The inferred protein is glycine- and tyrosine-rich and resembles a cement protein of the reef-building polychaete *Pragmatopoma californica* (a component of the quinone-tanned cement in the tubes built by these marine worms).

Figure 9 is a DNA alignment between the protein sequence shown in Figure 8 and a cement protein from the polychaete *Pragmatopoma californica*.

Figure 10A shows a PAGE gel showing the proteins expressed from *E. coli* cells transformed with a truncated coding sequence from clone 64.

Figure 10B shows a Western blot corresponding to Figure 10A.

Figure 11.a and 11.b show alignments of the truncated clone 64 protein with various natural proteins.

Figures 12.a and 12.b show histological sections of hamster skin stained with various conventional stains.

Figures 13.a, 13.b and 13.c show immunoperoxidase-stained sections of hamster skin.

EXAMPLES

Ticks

Ticks were reared according to Jones *et al.*, (1988). All three developmental stages of *Rhipicephalus appendiculatus* were fed on Dunkin Hartley guinea pigs. When not feeding, all ticks were maintained at 21 - 26°C and at 85% relative humidity.

Example 1 : Identification of proteins

Cement cones were collected from ticks (nymphs and adults) feeding on guinea pigs at different points of the attachment period. The cones were homogenised in phosphate-buffered saline (PBS), to extract soluble proteins, and in hot alkali and acid to extract less soluble components (Kemp *et al.*, 1982; Jaworski *et al.*, 1992).

Protein patterns were analysed using SDS-PAGE; the resulting gel is displayed as Figure 1A. Bands or spots corresponding with early expressed (group A) proteins and later expressed (group B) proteins were excised from the gel and used for the production of polyclonal antiserum. Good antisera could be obtained even against the less antigenic proteins provided that these proteins were not allowed to renature completely.

The resulting antisera were used to screen cDNA libraries and also for immunoblotting (see Figure 1B) and immunohistochemistry.

Proteins for which no good antiserum could be raised were blotted onto polyvinylidene difluoride membranes for amino-terminal sequence determination. For amino acid sequencing, samples were run on an Applied Biosystems 494A "Procise sequencer" (Perkin-Elmer, Applied Biosystems Division, Warrington U.K.).

Electroblotted samples are run using Applied Biosystems "Mini-Blott" cartridge in the place of the standard cartridge. Bands of interest are excised from the membrane and cut into 1 x 3mm pieces for insertion into the cartridge. These are sequenced using the manufacturer's recommended programme for membrane-bound samples (Schagger and von Jagow, 1987; Matsudaira, 1987).

This information was then used to design oligonucleotides to screen a tick cDNA library for clones of interest.

Example 2 : cDNA library construction

Salivary glands were excised from 20 male and 20 female adult *R. appendiculatus* specimens that had been feeding on guinea pigs for two days. The glands were collected on dry ice in an Eppendorf tube. Messenger RNA was isolated using the FastTrack mRNA isolation kit (Invitrogen).

To synthesize cDNA and insert the cDNA into the Lambda Zap II vector, the ZAP cDNA synthesis kit (Stratagene) was used. Prior to unidirectional insertion of the cDNA into the lambda vector, the nucleic acid was fractionated over a Sephacryl S-400 column (Pharmacia).

A library (termed d2-I) was constructed from low molecular weight cDNAs (ranging from approximately 100 to 2,000 base pairs). The higher molecular weight fraction was used to construct a second library (d2-II). Packaging was performed using Packagene (Promega) packaging extracts. Approximately 1.5 x 10^6 plaque-forming units (PFU) of each library were amplified in XL-1-Blue cells (Stratagene) for subsequent use.

Example 3 : Screening of the d2-II cDNA library

Phagemids were excised *in vivo* from a randomly selected fraction of the library, and used to generate double-stranded pBluescript SK(-) plasmids in XL1-Blue cells (Stratagene), as described by Short *et al.*, (1988).

XL1-Blue colonies were plated out on ampicillin-containing LB (Luria-Bertani) agar plates, supplemented with 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal, Melford Laboratories, UK) and isopropyl-β-D-thiogalactopyranoside (IPTG, Novabiochem) for blue/white colony selection.

About 75 plasmids (from white colonies) with inserts ranging from 250 to 1000 base pairs (as determined by digestion with *Pvu*II and electrophoresis over a 1% agarose gel) were selected for sequencing. The oligonucleotides used for sequencing correspond to the T3 and T7 primer sites in the pBluescript plasmid DNA.

Example 4 : Sequencing

Plasmids were purified from overnight cultures according to Goode and Feinstein (1992), alkali-denatured (Mierendorf and Pfeffer, 1987), and sequenced using the Sanger dideoxy-mediated chain termination reaction (Sanger and Coulson, 1975). Sequence data were analysed using the GCG sequence analysis software (Program Manual for the Wisconsin Package, 1994).

Protein database searches were performed at the National Centre for Biotechnology Information (NCBI) using the BLAST network service.

A number of clones were sequenced or partially sequenced. The sequences or partial sequences of those clones are shown in Figures 2 to 8 attached hereto. Explanations of the structure and features of the cloned sequences are given in the Brief description of the Figures above and in other parts of the description.

Example 5 : Production of the CemA Antiserum

An antiserum was produced against a prominent salivary gland protein of around 17kDa size.

For production of the polyclonal antiserum, salivary glands taken at day 6 of the adult feeding stage were homogenised in phosphate-buffered saline (PBS) and submitted to centrifugation (3 min; 12,000 x g). The proteins in the supernatant [i.e. the salivary gland extract (SGE)] were resolved over a 15% SDS-polyacrylamide gel, according to Laemmli (1970).

The gel was stained in an ice-cold 100 mM KCl solution and the 17 kDa protein was excised. The polyacrylamide section containing the protein was dried under vacuum, homogenised in PBS, mixed with an equal volume of Montanide ISA 50 adjuvant (Seppic, France) and subcutaneously injected into Dunkin Hartley guinea pigs. This procedure was repeated every 10 days. Serum was collected 10 days after the 4th injection.

Western blotting, performed according to Kyhse-Anderson (1984), showed a strong reaction of the antiserum with a 17kDa protein from the surface of cement cones (see Figure 1A). This protein, termed CemA, was present at all feeding stages of the ticks and could be easily obtained by washing of the cement cones in PBS.

Example 6 : Immunohistochemistry/ western blotting/ northern blotting/ *in situ* hybridisation

The polyclonal antisera were used in western blots and in staining sections of cement cones and salivary glands, taken at different stages of the feeding period. Where light-microscopy did not provide sufficient resolution to visualise the stain, electron microscopy was used.

For proteins against which no antisera could be produced, northern blots were instead performed using digoxygenin-labelled DNA probes constructed by random primer labelling (Sambrook *et al.*, 1989) using purified insert from the original clones. An anti-digoxygenin antiserum conjugated with alkaline-phosphatase allows probe detection. In fact, *in situ* hybridisation may be more suitable for localising and following the expression of genes in the salivary glands, since immunohistochemistry when performed on salivary glands often results in a high background.

In conjunction with the SDS-PAGE data, these techniques allow determination of the times at which specific proteins were expressed during the feeding period, where in the salivary glands they were produced and to which layer of the cone they contribute (thus better defining group A and B proteins).

Example 7 : Construction of genomic libraries and examination of differential expression.

In order to evaluate the differential expression of tissue cement protein genes, the following procedure is presently being followed. Genomic tick DNA, digested with suitable endonucleases is inserted into the Lambda Fix II vector (Stratagene), which allows for easy restriction mapping. Digoxygenin-labelled cDNA probes are used for library screening.

Regions flanking the coding sequences and introns are being sequenced and examined for the presence of sites that might play a role in the ordered expression of the proteins (for example ecdysteroid or heat-shock response elements). It was thought that comparison of genes of proteins expressed simultaneously might reveal common upstream or downstream sequences that are responsible for the regulation of gene expression. All group A protein genes, for example, may have identical recognition sites for regulatory factors.

Prospective regulatory regions are coupled to a reporter gene, for example luciferase, transfected into suitable cells (*e.g. Drosophila* cells), and submitted to functional

assays. Gel retardation, DNA protection or band-shift assays are also being performed to confirm the existence of functional regulatory domains.

It is possible that a single promoter region controls the simultaneous expression of a whole series of genes. These genes are then most probably localised in close proximity to one another on the genome. To investigate this possibility, the digoxygenin-labelled probes are being used to localise the genes on the genome by means of *in situ* hybridisation, Southern blotting and genomic library screening.

Expression of cement proteins may be regulated by one or more haemolymph-borne factor(s). This possibility is being investigated by incubating salivary glands taken from animals that have only just attached to their host in tissue culture medium containing haemolymph from ticks that have been feeding for 24 or 48 hours. Blotting (northern and western) or reverse transcriptase-PCR is then used to determine whether genes have been switched on or off.

Where there is evidence for a haemolymph-borne factor controlling the expression of cement genes, transplantation of salivary glands from ticks early in the feeding stage, to animals later in the feeding stage is being carried out, in case *in vitro* incubation experiments do not provide adequately clear results. This factor has been identified by HPLC and other standard techniques.

Example 8 : Aggregation/ cross-linking studies - protein expression

Aggregation (polymerisation) and cross-linking are being determined using proteins extracted from salivary glands and cement cones, and also using expressed recombinant proteins. Cement cone proteins are being examined directly by protein hydrolysis followed by detection of di- or tri-tyrosines among the amino-acids. Other assays are also being used for the detection of cross-linking enzymes and SDS-PAGE in the presence and absence of reducing agents to reveal inter- or intramolecular disulphide-bridges.

In addition, native group A and group B proteins are isolated from cement and salivary gland extracts by means of immunoprecipitation. This is only possible for the more soluble proteins. The molecular weight of the precipitated proteins is being determined by gel filtration. Comparisons are being made to the molecular weight of monomers as determined by SDS-PAGE and western blotting, or as calculated from the cDNA derived protein sequences.

Other components co-precipitating with a given (A or B) protein are being identified by screening the cDNA-library with oligonucleotide probes designed using N-terminal amino acid sequences.

The nature of eventual intermolecular bonds are also being determined. Hydrogen-bonds can be destroyed with urea and hydrophobic interactions with detergents. Detection of disulphide-bridges and cross-linked amino-acids can be performed as described previously (Creighton, 1989; Malencik *et al.*, 1996).

Studying native proteins is not always straightforward. For example, it can be difficult to extract enough protein to enable exhaustive study. Also, non-specific protein interactions may occur. Many of these problems can be solved by the use of recombinant proteins in their place.

Recombinant group A and group B proteins are therefore being expressed in bacteria or, where glycosylation and other post-translational modifications are crucial, in a eukaryotic (baculoviral) system. Those proteins which are not very soluble can be expressed in fusion with thioredoxin using, for example, the ThioFusion system (Invitrogen). In this system, the proteins are provided with oligohistidine-tags, allowing easy purification be means of nickel-agarose chromatography (Janknecht *et al.*, 1991). Enterokinase and/or thrombin sites are incorporated to remove tags and fused proteins from the cement protein after purification, in cases where this is necessary. In case aggregation of a protein takes place, or if interaction occurs between, for example, two different group A proteins, the nature of the bonds must be determined, as for the native proteins - see above. Expressed proteins which can be

recognised at all times by their histidine tags, or by the antisera were incubated with salivary gland extracts, in the absence and presence of specific and non-specific enzyme-inhibitors, in order to identify cross-linking.

The histidine-tagged expressed proteins can then be coupled to nickel-agarose and used in affinity-chromatography (Bugge *et al.*, 1992; Lu *et al.*, 1993) to isolate interacting proteins from salivary gland extracts or cement cones. These proteins can then be identified through the screening of cDNA libraries. By deletion and mutation experiments. domains or residues participating in the aggregation or cross-linking of recombinant proteins, are thus being identified.

Example 9 : Expression of truncated cement protein (64TRP) in bacteria

Oligonucleotides with appropriate restriction enzyme sites were designed to permit PCR cloning of an N-terminal fragment of clone 64, as shown in Figure 7. This fragment, known as 64P (amino acids 34 to 85) from the cDNA, was PCR cloned in-frame into the pET23 vector (Novagen). The construct, 64TRP (encoding amino acids 34 to 85), tagged onto the 6 x His-Tag of the pET23 vector, was obtained using standard PCR cloning methods (Sambrook *et al.*, *1989*). The plasmid was transformed into *E. coli AD494* cells (Sambrook *et al.*, 1989).

The expressed histidine-tagged expressed 64TRP (truncated cement protein) was purified by means of nickel-agarose affinity chromatography (Janknecht *et al.*, 1991). The protein was analysed by SDS-PAGE (Leammli, 1970) and the resulting gel is shown in Figure 10A. The expected protein band of approximately 7.8 kDa in size was obtained plus an extra upper band of about 10 kDa. The apparent size of the upper band indicates that it is not a dimer. Amino-terminal sequence analysis (Schagger and von Jagow, 1987; Matsudaira, 1987) of the two bands is currently being performed to determine the relationship between the two bands. A corresponding Western blot is shown in Figure 10B.

Example 10: Expression of full-length cement protein (64P) in insect cells using recombinant baculovirus

The full length clone of the cement protein 64P (i.e. 144 amino acids in length) was amplified from the cDNA using oligonucleotides containing appropiate restriction enzyme sites. inserted into the C129.1His baculovirus vector and transfected into *Sodoptera fugiperda* insect cells for eukaryotic expression (O'Reilly *et al., 1994*).

Example 11: Similarity of the amino acid sequence of the *R. appendiculatus* cement protein to sequences of other structural proteins

Protein database searches were performed at the National Centre for Biotechnology Information (NCBI) using the BLAST for the amino acid sequences of both the truncated and full length clone of the cement protein. Figures 11a and 11b show the relationships between the 64P, the truncated 64TRP and other structural proteins.

The first 40 amino acids of the cement protein are strongly collagen-like (Fig. 11b) and the rest of the sequence resembles keratin (Fig. 11a). The protein is glycine-rich and contains several repeats of the motif (C/S) 1-4 (Y/F) resembling structural proteins from *Drosophila melanogaster* (cuticular protein) and other insect egg shells, as well as vertebrate cytokeratins including mammalian keratin complex 2 basic protein, mouse keratin, human keratin, collagen type IV alpha and IPIB2 precusor. It would seem that the cement protein has been designed to resemble the skin proteins of the host, with the most likely aim of avoiding rejection of skin-tick attachment by the host's natural immune defence mechanisms. The compositional resemblance of 64P with its surrounding tissues may also facilitate the intimate binding between the cement cone and the surrounding skin tissues (see Examples 12 and 13).

Example 12 : Histological studies

Histological studies using either haematoxylin and eosin or van Gieson stains (Bancroft and Stevens, 1990) were performed on normal hamster skin sections and on

hamster skin sections on which *R. appendiculatus* ticks had been fed. Figure 12.a.A shows a normal skin section with intact epidermal, dermal and subcutaneous layers. The haematoxylin and eosin, and van Gieson stains indicate the expected tissue-types (i.e. basement membranes, collagen fibers and reticular fibers.) In skin sections on which *R. appendiculatus* had fed, the tick cement cone is clearly attached to the skin (Figure 12.b.A) and can be seen embedded in the dermis (Figure 12.a.B and 12.b.B) with the mouth parts *in situ*. Comparatively, the cement cone seems to resemble normal skin basement membranes, collagen/reticulin fibers, in tissue stain uptake. Also, there is no evidence of infiltration by inflammatory cells in relationship to the cement cone. The apparent absence of inflammation adds credence to the hypothesis that the structure and composition of the cement cone resembles that of skin tissues and is designed to avoid provoking a host response against the tick. The layered structure of the cement cone is clearly distinguishable in Figure 12.a.B. The apparent layering is probably due to the discontinuous deposition of cement proteins as the tick alternates between salivation (i.e. secretion) and imbibing of host fluids.

Example 13: Immunohistochemical studies/Western blotting

The denatured recombinant 64TRP protein was further purified by cation-ion exchange chromatography according to the manufacturer's recommendations (Pharmacia). The purified protein was used to raise polyclonal antiserum by subcutaneous injections of equal volumes of protein and Montanide ISA 50 adjuvant into Dunkin Hartley guinea pigs.

Western blotting (Kyhse-Anderson (1984)) showed a strong reaction of the antiserum to the denatured recombinant 64TRP cement protein bands (Figure 11B). Western blots with *R. appendiculatus* salivary gland and cement cone extracts from male and female ticks (prepared as previously described in Example 5) showed no reaction with the antiserum. The most probable explanation for the negative results is that the anti-64TRP antiserum binding epitope(s) were not readily available on the extracted proteins owing to the conformation of the proteins.

Using the anti-64TRP antiserum, immunohistochemical studies were performed on sections of both normal hamster skin, and *R. appendiculatus* salivary glands, cement cones and cement cones attached to hamster skin on which *R. appendiculatus* ticks had been attached (Coligan *et al.*, 1991).

Using normal skin, the anti-64TRP antiserum reacted strongly with the basement membranes, epidermal and dermal tissues as well as the hair follicular structures (compare Figure 13.a.A with the control serum, Figure 13.a.B). In skin from hamsters on which ticks had been fed, sections of individual cement cones reacted with the antiserum (Figures 13.b. and Figures 13.c.). The reactions were mainly with the outermost layer and inner layer attached to the basement membrane of the skin. The reaction pattern with cement cones may indicate that 64P is a cement protein that lines the cement cone, possibly acting as a glue that binds the cement cone to the surrounding epidermal and dermal tissues.

References

Arthur D.R. (1951) *Parasitology* 41, 66-81.

Brown S.J. and Askenase P.W. (1986) *Exp. Parasitol.* 62, 40-50.

Bugge T.H., Pohl J., Lonnoy O. and Stunnenberg H.G. (1992) *Embo J.* 11, 1409-1418.

Creighton T., (1989) *Protein Structure - A practical approach*, IRL Press, 155-168.

Davies F. (1988) *In*: Monath, T.P. (Ed.) *The Arboviruses: Epidemiology and Ecology*, CRC Press, Inc., Boca Raton, FL., 191-203.

Goode B.L. and Feinstein S.C. (1992) *Biotechniques* 12(3), 374-375.

Ichinose A., Bottenus R.E. and Davie E.W. (1990) *J. Biol. Chem.* 265, 13411-13414.

Janknecht R., de Martynoff G., Lou J., Hipskind R.A., Nordheim A., and Stunnenberg H.G. (1991) *PNAS* 88, 8972-8976.

Jaworski, D.C., Rosell R., Coons, L.B., and Needham G.R. (1992) *J. Med. Entomol.* 29, 305-309.

Kemp D.H., Stone B.F. and Binnington K.C. (1982) *In*: Obenchain F.D. and Galun R. (Eds.) *Physiology of Ticks*. Pergamon Press, Oxford, New York, Toronto, Sydney, Paris, Frankfurt, 119-68.

Kyhse-Anderson J. (1984) *J. Biochem. Biophys. Methods* 10, 203-209.

Laemmli V.K. (1970) *Nature* 277, 680-685.

Lu T., Van Dyke M. and Sawadogo M. (1993) *Anal. Biochem.* 213, 318-322.

Malencik D.A., Sprouse J.F., Swanson C.A. and Anderson S.R. (1996) *Anal. Biochem.* 242, 202-213.

Matsudaira P. (1987) *J. Biol. Chem.* 262, 10035-10038.

Mierendorf R.C. and Pfeffer D. (1987) *Methods Enzymol.* 152, 556-562.

Moorhouse D.E. and Tatchell R.J. (1966) *Parasitology* 56, 623-632.

Norval R.A.I., Barrett J.C., Perry B.D. and Mukhebi, A.W. (1992) *In*: Fizas B., Petney T. and Horak I. (Eds.) *Tick Vector Biology - Medical and Veterinary Aspects.* Springer-Verlag, Berlin Heidelberg.

Norval R.A.I., Perry B.D. and Young A.S. (1992) *The epidemiology of theileriosis in Africa.* Academic Press, London.

O'Reilly D.R., Miller L.K. and Luckow, V.A. (1994) *Baculovirus expression vectors - A laboratory manual*, Oxford University Press.

Sambrook *et al.*, Molecular Cloning: a Laboratory Manual: 2nd edition, , 1989, Cold Spring Harbor Laboratory Press.

Sanger F. and Coulson A.R. (1975) *J. Mol. Biol.* 94(3), 441-448.

Schagger H. and von Jagow G. (1987) *Anal. Biochem.*, 166, 368-379.

Shapiro S.Z., Voigt W.P., and Ellis J.A. (1989) *Exp. Appl. Acarol.* 7, 33-41.

Siegel R.C. (1979) *Int. Rev. Conn. Tissue Res.* 8, 73-118.

Sonenshine D.E. (1991) *Biology of Ticks*, Vol. 1. New York Oxford, Oxford Univ.

Press., 447.

Sugumaran M., Giglio L, Kundzicz H., Saul S. and Semensi V. (1992) *Arch. Insect. Biochem. Physiol.* 19, 271-283.

Walker A.R., Fletcher J.D. and Gill H.S. (1985) *Int. J. Parasitol.* 15, 81-100.

Watson J.D., Gilman M., Witkowski J and Zoller M. (1994) *Recombinant DNA (2nd edition)*, Scientific American Books.

CLAIMS

1. A tissue cement protein having the amino acid sequence shown in Figure 3 or Figure 7 or containing any one of the partial amino acid sequences shown in any one of Figures 2, 4 to 6 and 8, related tissue cement proteins from blood-feeding parasites, preferably ticks, and functional equivalents thereof.

2. The tissue cement protein of claim 1 that is of the group A subtype as hereinbefore defined.

3. The tissue cement protein of claim 1 that is of the group B subtype as hereinbefore defined.

4. The tissue cement protein of any one of the preceding claims that binds to vertebrate tissues.

5. The tissue cement protein of any one of the preceding claims that is derived from a blood-feeding ectoparasite.

6. The tissue cement protein of claim 5 that is derived from ticks.

7. The tissue cement protein of claim 6 that is derived from Ixodid ticks.

8. The tissue cement protein of claim 7 that is derived from *Rhipicephalus appendiculatus*.

9. The tissue cement protein of any one of the preceding claims that is associated with one or more carbohydrate moieties.

10. The tissue cement protein of claim 9 that is associated with one or more glycosaminoglycan moieties.

11. The tissue cement protein of any one of the preceding claims that is expressed in recombinant form.

12. The tissue cement protein of any one of the preceding claims that is associated with one or more peptides or polypeptides.

13. The tissue cement protein according to claim 12 which is associated with one or more self molecules to form a homodimer, homotrimer or homotetramer unit.

14. The tissue cement protein according to claim 12 associated with one or more non-self molecules to form a heterodimer, heterotrimer or heterotetramer unit.

15. The tissue cement protein of any one of the preceding claims that has been genetically or chemically fused to one or more peptides or polypeptides.

16. The tissue cement protein of any one of the preceding claims that has been cross-linked to one or more peptides or polypeptides.

17. The tissue cement protein of any one of the preceding claims attached to a label.

18. The tissue cement protein of any one of the preceding claims attached to a toxin.

19. The tissue cement protein of any one of the preceding claims that is bound to a support, such as a resin.

20. A pharmaceutical composition comprising a mixture of group A and group B tissue cement proteins according to any preceding claim in the absence of other parasite saliva proteins but in the presence of one or more compounds capable of cross-linking said tissue cement proteins, in conjunction with a pharmaceutically-

acceptable excipient.

21. A pharmaceutical composition comprising a mixture of group A and group B tissue cement proteins according to any one of claims 1 to 19 in the absence of other parasite saliva proteins in conjunction with a pharmaceutically-acceptable excipient.

22. A pharmaceutical composition comprising a mixture of group A and group B tissue cement proteins according to any one of claims 1 to 19 together with those saliva proteins necessary for the cement-hardening process, but in the absence of other parasite saliva proteins, in conjunction with a pharmaceutically-acceptable excipient.

23. The tissue cement protein according to any one of claims 1 to 19 or a pharmaceutical composition of any one of claims 20 to 22 for use in therapy.

24. Use of the tissue cement protein of any one of claims 1 to 19 as a pharmaceutical.

25. The tissue cement protein of any one of claims 1 to 19 for use as a vaccine or as a component of a vaccine.

26. Use of the tissue cement protein of any one of claims 1 to 19 as a vaccine or vaccine component.

27. A vaccine comprising the tissue cement protein of any one of claims 1 to 19.

28. A method of production of the vaccine of claim 27 comprising immunising an animal with the tissue cement protein of any one of claims 1 to 19.

29. A method of bonding animal tissue comprising bringing an animal tissue into conjunction with one or more tissue cement proteins of any one of claims 1 to 19 that are capable of forming a hardened cement.

30. The tissue cement protein of any one of claims 1 to 19 or a pharmaceutical composition of any one of claims 20 to 22 for use in the temporary or permanent bonding of tissues.

31. The tissue cement protein of any one of claims 1 to 19 for use as a protective immunogen in the control of diseases caused by infections transmitted by arthropod parasites.

32. A nucleic acid molecule which encodes a tissue cement protein of any one of claims 1 to 19 or which hybridises with said nucleic acid molecule under standard hybridisation conditions.

33. The nucleic acid molecule of claim 32 which comprises DNA, cDNA or RNA.

34. The nucleic acid molecule of claim 32 or claim 33 which comprises DNA.

35. A cloning or expression vector comprising a nucleic acid molecule of any one of claims 32 to 34.

36. The vector of claim 35 which is virus based.

37. The vector of claim 36 which is baculovirus based.

38. A host cell transformed or transfected with the vector of any one of claims 35 to 37.

39. A transgenic animal that has been transformed by the nucleic acid molecule of any one of claims 31 to 34 or a vector of one of claims 35 to 38.

40. A method of preparing a tissue cement protein of any one of claims 1 to 19, comprising expressing a vector according to any one of claims 35 to 37 in a host cell and culturing said host cell under conditions where said protein is expressed, and recovering said protein thus expressed.

FIG. 1B



FIG. 1A



SUBSTITUTE SHEET (RULE 26)

FIG. 2

```
1    AAACCAAGGCAGGACACAGCAGCCATGAAGGCCTTCGTTGCAGTCGCCCTTTTGTCTGCA   60
                M  K  A  F  V  A  V  A  L  L  S  A

61   GTTTCCGTGGCACATGCTGCCCTCAAGACTGACGTAGCCAGTGGACCTGCCGGTTCTGGT  120
     V  S  V  A  H  A  A  L  K  T  D  V  A  S  G  P  A  G  S  G

121  GCACTAAGTCTAGGAGTTGGAGGCTTCCCGTCCGGTGCTTCGCTTGGCAGCCTTAGTGGC  180
     A  L  S  L  G  V  G  G  F  P  S  G  A  S  L  G  S  L  S  G

181  GTAACCCTCTCTGGTGCTGGCTCTTCCGTGTCTGGCCGCCCTGGATCCCCTGGATCGGCT  240
     V  T  L  S  G  A  G  S  S  V  S  G  R  P  G  S  P  G  S  A

241  GGTCCTAGCTCTGGACCCGCAGTGTCG  267
     G  P  S  S  G  P  A  V  S
```

SUBSTITUTE SHEET (RULE 26)

FIG. 3

```
1    CGGACGCACACTCCTGCAGGAAGGTCATCTAGTTCCGCCAACATGAAGCTGCTCTGTGCA   60
                                                 M  K  L  L  C  A

61   CTAGCCCTCGTTGCCCTTGGACTTCCATTCGGCAGCGCTTACCTTGGTGGCTTCGGCGGC  120
     L  A  L  V  A  L  G  L  P  F  G  S  A  Y  L  G  G  F  G  G

121  CTCGGTGGTTGGGGTGGCGGTCTCGGTGCCATCTTTGGCCCAGGAGCTTATCCCGGTTTC  180
     L  G  G  W  G  G  G  L  G  A  I  F  G  P  G  A  Y  P  G  F

181  TATGGCCTTAACAGCGTGCACCTCTTGGGCGGCAGGTTCCACCATCTCTTCGGGCGATTC  240
     Y  G  L  N  S  V  H  L  L  G  G  R  F  H  H  L  F  G  R  F

241  CCGCCACCACCCGGTATTGGAGCTGCTGAAGCGCAGGGGAACCTAAGCCCATACCCTCTT  300
     P  P  P  P  G  I  G  A  A  E  A  Q  G  N  L  S  P  Y  P  L

301  GACATCAACACCGTCCAAGACCCGAACTGGCCACCCCATGGTACGCGTTGTCTACGGCGG  360
     D  I  N  T  V  Q  D  P  N  W  P  P  H  G  T  R  C  L  R  R

361  AGTCTTGCGGGAGCGCCTCTGACCCTGACCAGTCCCAATTCCACAGGATGTGCCTGTCCC  420
     S  L  A  G  A  P  L  T  L  T  S  P  N  S  T  G  C  A  C  P
```

```
421  AGTCCCCATTCCAGTGCCCCAGCCATACCCAGTCCCACACCCACGACAAGTTCCATACCC  480
     S  P  H  S  S  A  P  A  I  P  S  P  T  P  T  T  S  S  I  P

481  AGTGCCTAGTCCCTACCCCGTCCCAATCCACAGTAACACCGAAGTTCACAAGACCGACGT  540
     S  A

541  CGTCGCCGCTACTCCAGGAGGACCAGTCCTGCTCGGAGTCGGTGTCACCGGTGTCAGGCC  600

601  AGGCGAACCAAGGGTCGTGGCCTAAGCTTGATCCAATAGAAAGTCATAACAATTTAGTCA  660

661  GTGAGCTCCACGTAAATTATGCATTACAAATAAAGAAAAGTTTGTCTGGCAGTAAAAAAA  720

721  AAAAAAAAAA  730
```

FIG. 3(CONTD.)

SUBSTITUTE SHEET (RULE 26)

FIG. 4

```
1   GATCGGCACGAGGTCAAGGGAGCCCTCCTTCAGCAACAACAAGCATCGCAGGTTAAGGGA   60
    D  R  H  E  V  K  G  A  L  L  Q  Q  Q  Q  A  S  Q  V  K  G

61  GCCCTCAAGGGAGCAATCAAGGGTGGTCTTCTTCAGCAACAAGCCCAATCCCAAGTCCAA  120
    A  L  K  G  A  I  K  G  G  L  L  Q  Q  Q  A  Q  S  Q  V  Q

121 GGAGCTCTTAAGGGAGCCGTCAAGGGAGCCCTCCTTCAGCAACAACAGGCATCACAGGTC  180
    G  A  L  K  G  A  V  K  G  A  L  L  Q  Q  Q  Q  A  S  Q  V

181 AAGGGAGCCCTCAAGGGAGCCATCAAGGTCTGTCTCCTTCATCAGCAAGCCCAATCCCAA  240
    K  G  A  L  K  G  A  I  K  V  C  L  L  H  Q  Q  A  Q  S  Q

241 TCCCAAGTTCAGGGAGCTCTTAAGGGAGCTG  271
    S  Q  V  Q  G  A  L  K  G  A
```

SUBSTITUTE SHEET (RULE 26)

FIG. 5

```
1   GGAAGTAGCGAGCATCCGCACTGGGGTCTTTTTGGCTGCATTTGCTTTTCTTCTTTCAGC   60
      E  V  A  S  I  R  T  G  V  F  L  A  A  F  A  F  L  L  S  A

61  GATCCATAACAATGGCCAGTCATGTGTAGATGCAGCCCCCACTCGACGTCCTATGCCATC  120
      I  H  N  N  G  Q  S  C  V  D  A  A  P  T  R  R  P  M  P  S

121 TCCTCCTGGATGTGCTGGTCCTGGCTGTTTTACTGGTATTGCTACTCTTCTAAGACCTGG  180
      P  P  G  C  A  G  P  G  C  F  T  G  I  A  T  L  L  R  P  G

181 TCAAGGACAGCAACCTGGTCAAGGACAGCAACCTGGTCAAGGGCGTCCTCCAATGCCACG  240
      Q  G  Q  Q  P  G  Q  G  Q  Q  P  G  Q  G  R  P  P  M  P  R

241 TCCAGGACCTGTTCCAGGAACATCTGGATCACCTCAAGGAAGACCCAATGGAGCACCTCG  300
      P  G  P  V  P  G  T  S  G  S  P  Q  G  R  P  N  G  A  P  R

301 TCCAGGACCTGTTCCTGGAACATCTGGATCACCTCAAGGAAGACCTAACGCAAGACCTCG  360
      P  G  P  V  P  G  T  S  G  S  P  Q  G  R  P  N  A  R  P  R

361 TCCAGGACCTGTTCCTGGAACACCAACTGTATCCTCTCCCGGATCATCTCCTGGGTCATC  420
      P  G  P  V  P  G  T  P  T  V  S  S  P  G  S  S  P  G  S  S
```

```
421  TCCAGGAATATCTCTAGGAACGCCTCTAGGAACACCTCTAGGAACACCTCAAGGATCACC  480
       P   G   I   S   L   G   T   P   L   G   T   P   L   G   T   P   Q   G   S   P

481  TTTTGGATCATCTCTTGGATCATCGATAGGATCACCTCCTGCAACATCTCCTGGATCATC  540
       F   G   S   S   L   G   S   S   I   G   S   P   P   A   T   S   P   G   S   S

541  TTCTCCGTCACCTCCTGGATCAGCGAATGTGAACCTGCTGGGTCCTCGACCAATTCGCGG  600
       S   P   S   P   P   G   S   A   N   V   N   L   L   G   P   R   P   I   R   G

601  TCCTGGAAGGCATTGACGGGACCAGTTCTGCTGTGTATTCCTCCGTGCACAATGAGGGAA  660
       P   G   R   H

661  GGCATTGATGGGACCAGTTCTGCTGTGTATTTCTCCGTGCACAGTGAGGGAATCTATCAA  720

721  TAGTGCAATAA  731
```

FIG. 5(CONTD.)

SUBSTITUTE SHEET (RULE 26)

```
1   GGCTTCGGCAGCCCACTCAGCGGTTTCGGCAGCCCACTCAGCGGTTTCGGCAGCCCACTC   60
    G  F  G  S  P  L  S  G  F  G  S  P  L  S  G  F  G  S  P  L

61  AGCGGCTTCGGCAGCCCACTCAGCGGATTCGGTAGCCCACTCAGCGGATTCGGTAGCCCA  120
    S  G  F  G  S  P  L  S  G  F  G  S  P  L  S  G  F  G  S  P

121 CTCAGCGGATTCGGTAGCCCATTCGGCAGCTACGGTCCCCTGTCCATGGGTCTCGGAGCC  180
    L  S  G  F  G  S  P  F  G  S  Y  G  P  L  S  M  G  L  G  A

181 CCCAGGAGATTCCCCGGCGACCTCCGCCTCATCTCTGAGCCCACCTCCCGCCTTCCCGTT  240
    P  R  R  F  P  G  D  L  R  L  I  S  E  P  T  S  R  L  P  V

241 AGCGATGCCGTCTACACCGCTGTCGTCCAGCCCGTCACAAGCGCAGTGGTCCACACCGAG  300
    S  D  A  V  Y  T  A  V  V  Q  P  V  T  S  A  V  V  H  T  E

301 GGTCCCCATGTCACCGGCCAAGTACAGGAACACGTTGCAATCTAAGCTTTTCTAACCGCA  360
    G  P  H  V  T  G  Q  V  Q  E  H  V  A  I

361 AGCTATATTACGACGGATTAGTCAACACAGTCATCTTAAGCAAATGTATCTAAAATAAAA  420

421 TTTATCTGCCT  431
```

FIG. 6

FIG. 7

```
1   GGAGATCACCTGCTTGCAAAGGACAACGTCCTAACACAGCCGCAAAATGAAAGCTTTCTT   60
                                                  M  K  A  F  F

61  CGTTCTTTCCCTTCTTTCAACCGCCGCACTGACGAATGCAGCAAGGGCTGGTCGTCTTGG  120
     V  L  S  L  L  S  T  A  A  L  T  N  A  A  R  A  G  R  L  G

121 AAGCGACCTGGATACATTTGGAAGGGTACACGGTAACCTATATGCCGGCATCGAAAGAGC  180
     S  D  L  D  T  F  G  R  V  H  G  N  L  Y  A  G  I  E  R  A

181 TGGCCCTCGTGGATACCCAGGGCTTACCGCATCGATTGGAGGCGAAGTGGGTGCACGACT  240
     G  P  R  G  Y  P  G  L  T  A  S  I  G  G  E  V  G  A  R  L

241 CGGTGGTCGTGCCGGTGTGGGAGTGAGCAGCTACGGCTATGGTTACCCTTCATGGGGCTA  300
     G  G  R  A  G  V  G  V  S  S  Y  G  Y  G  Y  P  S  W  G  Y

301 TCCGTATGGTGGATACGGTGGATACGGTGGATACGGTGGATACGGTGGATATGATCAGGG  360
     P  Y  G  G  Y  G  G  Y  G  G  Y  G  G  Y  G  G  Y  D  Q  G
```

```
361  TTTTGGCTCTGCATACGGCGGCTACCCCGGCTACTATGGCTACTACTATCCCAGTGGCTA  420
       F  G  S  A  Y  G  G  Y  P  G  Y  Y  G  Y  Y  Y  P  S  G  Y

421  CGGTGGGGGCTACGGTGGTAGCTACGGTGGCAGCTACGGTGGTAGCTACACCTATCCCAA  480
     G  G  G  Y  G  G  S  Y  G  G  S  Y  G  G  S  Y  T  Y  P  N

481  CGTTCGGGCTTCAGCTGGTGCCGCAGCTTGAGCTTCTCCTTCAGCGTCACAGTAAGAAAT  540
       V  R  A  S  A  G  A  A  A  *

541  CATGGAGCACCCGATCGAGAAATACAGAGGTTCTCAAAAGCGTACGGGATGCCAACCAGC  600

601  AAGAAATTGCGCCGCAAAATGTTGAGAACAAATACAAGTTTTCTGTAAAAAAAAAA      656
```

FIG. 7(CONTD.)

FIG. 8

```
1   ACGGACTAGGTTTCGCTGGCGTCCCTCTTATTGGCGGATACGGCTACGGTCCTTTCGTAG   60
      G  L  G  F  A  G  V  P  L  I  G  G  Y  G  Y  G  P  F  V  G

61  GAGCCTTCGCGTACGGCTTGTGGGGTGGCCTCGGTGGCTATGGCTACCCTGCCTTCGGAC  120
      A  F  A  Y  G  L  W  G  G  L  G  G  Y  G  Y  P  A  F  G  L

121 TCTCCTGGGTTCCACATGGTTTTGGAGGCTTTGGAGCTTCTCCGTCTGCTGCTGGTTTCC  180
      S  W  V  P  H  G  F  G  G  F  G  A  S  P  S  A  A  G  F  R

181 GCTCGCTTTGGAGCCTCTT  199
      S  L  W  S  L
```

FIG. 9

```
R.appendiculatus
      GLGFAGVPLIGGYGYGPFVGAFAYGLWGGLGGYGYPAFGLSWVPHGFGGFGASP
      |.|: |.. :||||||: :|:::|| : :|||||.| :  | :::||:||::
      GYGY.GAKKVGGYGYGAKLGGYGYG..AKIGGYGYGAKSGIQV.RALGGYGAGA
P.californica
```

FIG. 10

EXPRESSION OF RECOMBINANT (TRUNCATED) STRUCTURAL PROTEIN, 64TRP IN *Escherichia coli* CELLS



SDS-PAGE: (A) AND (B) WESTERN BLOT (USING ANTI-64TRP ANTISERUM) AND COOMASSIE BLUE STAINED 15% POLYACRYLAMIDE GEL, RESPECTIVELY OF IPTG-INDUCED *E.coli* CELLS EXPRESSING 64TRP PROTEIN. SAMPLES WERE SOLUBULISED AT 100^{O} C IN SDS PRIOR TO LOADING THE GELS.

FIG. 11a cDNA inferred sequence alignment between the protein sequence of 64P and other related structural proteins.



Sequences are: ker1=keratin complex2 basic protein, ker2=mouse keratin, ker3=mouse epidermalK protein, ker4=human keratin protein, 64P=*R. appendiculatus* putative structural protein

FIG. 11b cDNA inferred sequence alignment between the protein sequences of 64TRP and other structural proteins.



Sequences are: col1=Glycine-rich GX protein-motif LGG, col2=collagen type Iv alpha protein, col3=IPIB2 precursor protein, col4=Glycine rich cell wall protein, 64TRP=*R. appendiculatus* truncated structural protein

FIG. 12a HISTOLOGICAL STUDIES OF THIN HAMSTER SKIN SECTIONS STAINED WITH HAEMATOXYLIN AND EOSIN



(A) AND (B) = HISTOLOGICAL SECTIONS OF HAMSTER SKIN STAINED WITH HAEMATOXYLIN AND EOSIN; (A)=NORMAL SKIN SECTION SHOWING EPIDERMIS-1, DERMIS-2 AND SUBCUTANEOUS LAYER-3. (B)=SKIN SECTION SHOWING AN EMBEDDED TICK *(R.appendiculatus)* CEMENT CONE. STAINING: PINK= BASEMENT MEMBRANES/COLLAGEN FIBRES, UNSTAINED=RETICULIN FIBRES, BLUE=CELL NUCLEI. C REFERS TO CEMENT CONE AND M TICK MOUTH PARTS. ABOUT 20x

SUBSTITUTE SHEET (RULE 26)

FIG. 12b

HISTOLOGICAL STUDIES OF THIN HAMSTER SKIN SECTIONS STAINED WITH HAEMATOXYLIN AND EOSIN, AND VAN GIESON STAINS.

A



B

(A) AND (B) = HISTOLOGICAL SECTIONS OF HAMSTER SKIN SHOWING ATTACHED TICK *(R. appendiculatis)* CEMENT CONES (i.e. POST FEEDING) STAINED WITH (A) HAEMATOXYLIN AND EOSIN STAIN (H & E), (B) VAN GIESON STAIN. 1=EPIDERMIS, 2=DERMIS AND 3=SUBCUTANEOUS LAYER. STAINS: H & E-PINK=BASEMENT MEMBRANES/COLLAGEN FIBRES, BLUE=CELL NUCLEI, VAN GEISON-RED=COLLAGEN FIBRES, YELLOW=BASEMENT MEMBRANES/RETICULIN AND ELASTIN FIBRES. C=CEMENT CONE AND M= TICK MOUTHPARTS. ABOUT 20x.

FIG. 13a IMMUNOPEROXIDASE STUDIES ON HAMSTER SKIN SECTIONS USING ANTI-64TRP ANTISERUM



(A) AND (B) = NORMAL HISTOLOGICAL SECTIONS OF HAMSTER SKIN INCUBATED WITH ANTI-64TRP ANTISERUM AND A POSITIVE CONTROL ANTISERUM RESPECTIVELY, AND DEVELOPED WITH PEROXIDASE LINKED SECONDARY ANTISERUM. 1= EPIDERMIS, 2=DERMIS AND 3= SUBCUTANEOUS LAYER; *=AREAS OF SKIN SHOWING POSITIVE REACTIONS TO ANTI 64TRP ANTISERUM. ABOUT 20x

FIG. 13b IMMUNOPEROXIDASE STUDIES ON *R. appendiculatus* CEMENT CONE SECTIONS USING ANTI-64TRP ANTISERUM



(A) AND (B) = THIN SECTIONS OF *R. appendiculatus* CEMENT CONES INCUBATED WITH EITHER A POSITIVE CONTROL ANTI-SERUM OR ANTI-64 TRP ANTI-SERUM RESPECTIVELY, AND DEVELOPED WITH PEROXIDASE LINKED SECONDARY ANTISERUM. 1=PART OF SKIN EPIDERMIS *=AREAS OF SKIN SHOWING POSITIVE REACTIONS TO ANTI-64TRP ANTI-SERUM. ABOUT 20x

SUBSTITUTE SHEET (RULE 26)

FIG. 13c IMMUNOPEROXIDASE STUDIES USING ANTI-64TRP ANTISERUM ON THIN HAMSTER SKIN SECTIONS POST FEEDING WITH *R. appendiculatus*



(A) AND (B) = THIN SECTIONS OF HAMSTER SKIN POST-FEEDING WITH *R. appendiculatus* SHOWING A CEMENT CONE STILL ATTACHED, INCUBATED WITH ANTI-64TRP ANTISERUM AND A POSITIVE CONTROL ANTISERUM RESPECTIVELY, AND DEVELOPED WITH PEROXIDASE LINKED SECONDARY ANTISERUM. 1=EPIDERMIS, 2=DERMIS AND 3=SUBCUTANEOUS LAYER. * = AREAS OF SKIN SHOWING POSITIVE REACTIONS TO ANTI 64TRP ANTISERUM. ABOUT 20x

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

[redacted]tional Application No
PCT/GB 98/03397

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/12 C12N15/86 C12N15/62 C12N5/10 C07K14/435
A61K38/17 A61K39/00 A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N C07K A61K A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	A.L. CRAMPTON ET AL.: "Expression sequenced tags and new genes from the cattle tick, Boophilus microplus" EMBL SEQUENCE DTABASE,11 September 1997, XP002093748 Heidelberg, FRG Boophilus microplus EST 198 putative nuclear antigen mRNA sequence; Accession no. U92768; & EXP. APPL. ACAROL. , vol. 22, no. 3, 1998, pages 177-186, --- -/--	1

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
19 February 1999	05/03/1999

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Hornig, H

2

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category ³	Citation of document, with indication,where appropriate. of the relevant passages	Relevant to claim No.
A	D.C. JAWORSKI ET AL.: "Tick (Acari: Ixodidae) attachement cement and salvary gland cells contain similar immunoreactive polypeptides" JOURNAL OF MEDICAL ENTOMOLOGY, vol. 29, no. 2, March 1992, pages 305-309, XP002093749 Published by The Entomological Society of America, Lanham, Maryland, US cited in the application see the whole document ---	1-40
A	D.C. JAWORSKI ET AL.: "Evidence that a 90 kDa tick salivary galnd polypeptide is a cement protein" F.DUSBÁBEK AND V. BUKVA (EDS.): MODERN ACAROLOGY, ACADEMIA PRAGUE, vol. 1, 1991, pages 335-340, XP002094114 SPB Academic Publishing bv, The Hague, NL Modern Acarology Volume I. Proceedings of the VIII International Congress of Acarology, Held in Ceske Budejovice, Czechoslovakia, 6-11 August 1990; see the whole document ---	1-40
A	S. SHAPIRO ET AL.: "Acquired resistance to Ixodid Ticks induced by Tixk cement antigen" EXPERIMENTAL & APPLIED ACAROLOGY, vol. 7, 1989, pages 33-41, XP002093750 Elsevier Science Publishers B.V., Amsterdam, NL cited in the application see the whole document ---	1-40
A	S.Z. SHAPIRO ET AL.: "Tick antigens recognized by serum from a guinea pig resistant to infestation with the tick Rhipicephalus appendiculatus" J. PARASITOLOGY, vol. 72, no. 3, June 1986, pages 454-463, XP002093751 see the whole document ---	1-40
A	WANG H ET AL: "COMPARISON OF THE PROTEINS IN SALIVARY GLANDS, SALIVA AND HAEMOLYMPH OF RHIPICEPHALUS APPENDICULATUS FEMALE TICKS DURING FEEDING" PARASITOLOGY, vol. 109, no. 4, November 1994, pages 517-523, XP002050816 see the whole document ---	1-40

-/--

2

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
A	S.J. BROWN AND P.W. ASKENASE: "Amblyomma americanum: Physicochemical Isolation of a protein derived from the ick slivary gland that is capable of inducing immune resistance in guinea pigs" EXPERIMENTAL PARASITOLOGY, vol. 62, no. 1, August 1986, pages 40-50, XP002093752 NEW YORK, US cited in the application see the whole document	1-40
A	G.R. NEEDHAM ET AL.: "Characterization of Ixodid Tick salivary-gland gene products, using recombinant DNA technology" EXPERIMENTAL & APPLIED ACAROLOGY, vol. 7, 1989, pages 21-32, XP002093753 Elsevier Science Publishers, B.V., Amsterdam, NL cited in the application see the whole document	1-40
A	GB 2 142 334 A (INT CENTRE OF INSECT PHYSIOLOG) 16 January 1985 see the whole document	1-40

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 98/ 03397

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 28, 29 and 24, 26 (as far as in vivo methods are concerned) are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

ation on patent family members

tional Application No
PCT/GB 98/03397

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2142334 A	16-01-1985	NONE	

PATENT COOPERATION TREATY

PCT

REC'D 17 MAR 2000

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
P018303WO		
International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/GB98/03397	12/11/1998	12/11/1997
International Patent Classification (IPC) or national classification and IPC		
C12N15/12		
Applicant		
NATIONAL ENVIRONMENTAL RESEARCH COUNCIL et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 9 sheets, including this cover sheet.

   ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

   - I ☒ Basis of the report
   - II ☐ Priority
   - III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
   - IV ☒ Lack of unity of invention
   - V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations suporting such statement
   - VI ☐ Certain documents cited
   - VII ☐ Certain defects in the international application
   - VIII ☒ Certain observations on the international application

Date of submission of the demand	Date of completion of this report
14/06/1999	14.03.00
Name and mailing address of the international preliminary examining authority: European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Paresce, D Telephone No. +49 89 2399 8995

Form PCT/IPEA/409 (cover sheet) (January 1994)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB98/03397

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-34 as originally filed

Claims, No.:

1-40 as originally filed

Drawings, sheets:

1/19-19/19 as originally filed

2. The amendments have resulted in the cancellation of:

☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:

☐ restricted the claims.

☒ paid additional fees.

☐ paid additional fees under protest.

☐ neither restricted nor paid additional fees.

2. ☐ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is

   ☐ complied with.

   ☒ not complied with for the following reasons:

   see separate sheet

4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

   ☒ all parts.

   ☐ the parts relating to claims Nos. .

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-40, partially
	No:	Claims	1-40, partially
Inventive step (IS)	Yes:	Claims	1-40, partially
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-23, 25, 27, 30-40
	No:	Claims	

2. Citations and explanations

   see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

The documents mentioned in this communication are numbered as in the search report, i.e. D1 corresponds to the first document of the search report.

Re Item IV

Lack of unity of invention

The claims of present application relate to eight different inventions. The separate inventions/groups of invention are:

1) Claims 1-40, partially, are directed to a tissue cement protein having the amino acid sequence shown in Figure 3, as well as to functional equivalents of said tissue cement protein. The claims are further directed to said tissue cement protein that has been genetically or chemically fused to one or more peptides, pharmaceutical compositions comprising said tissue cement protein, as well as methods of use of said protein in therapy, as a vaccine, for bonding animal tissues, or for use as a protective immunogen in the control of diseases caused by infections transmitted by parasites. The claims are directed to a nucleic acid molecule which encodes said tissue cement protein, a nucleic acid molecule specifically hybridizing with said molecule, vectors comprising said nucleic acid molecule, host cells transformed with said molecule, a transgenic animal transformed with said molecule, and a method of preparing said tissue cement protein.

2) Claims 1-40, partially, are directed to a tissue cement protein having the amino acid sequence shown in Figure 7 and functional equivalents thereof. The claims are further directed to said tissue cement protein that has been genetically or chemically fused to one or more peptides, pharmaceutical compositions comprising said tissue cement protein, as well as methods of use of said protein in therapy, as a vaccine, for bonding animal tissues, or for use as a protective immunogen in the control of diseases caused by infections transmitted by parasites. The claims are directed to a nucleic acid molecule which encodes said tissue cement protein, a nucleic acid molecule specifically hybridizing with said molecule, vectors comprising said nucleic acid molecule, host cells transformed with said molecule, a transgenic animal transformed with said molecule, and a method of preparing said tissue cement protein.

3) Claims 1-40, partially, are directed to a tissue cement protein containing a partial amino acid sequence shown in Figure 2. The claims are further directed to pharmaceutical compositions comprising said tissue cement protein, and methods of use of said protein (see invention 1 above).

4) Claims 1-40, partially, are directed to a tissue cement protein containing a partial amino acid sequence shown in Figure 4. The claims are further directed to pharmaceutical compositions comprising said tissue cement protein, and methods of use of said protein (see invention 1 above).

5) Claims 1-40, partially, are directed to a tissue cement protein containing a partial amino acid sequence shown in Figure 5. The claims are further directed to pharmaceutical compositions comprising said tissue cement protein, and methods of use of said protein (see invention 1 above).

6) Claims 1-40, partially, are directed to a tissue cement protein containing a partial amino acid sequence shown in Figure 6. The claims are further directed to pharmaceutical compositions comprising said tissue cement protein, and methods of use of said protein (see invention 1 above).

7) Claims 1-40, partially, are directed to a tissue cement protein containing a partial amino acid sequence shown in Figure 8. The claims are further directed to pharmaceutical compositions comprising said tissue cement protein, and methods of use of said protein (see invention 1 above).

8) Claims 1-40, partially, are directed to related tissue cement proteins from blood-feeding parasites. The claims are further directed to pharmaceutical compositions comprising said tissue cement protein, and methods of use of said protein (see invention 1 above).

The separate inventions/groups of invention are not so linked as to form a single general **inventive** concept (Rule 13.1 PCT) for the following reasons:

The general concept underlying the eight above identified inventions of the present application can be seen as the provision of tissue cement proteins from

blood-feeding parasites, preferably ticks. However, this general concept is not considered novel having regard to the state of the art as illustrated by, for example, D2, D3, or D8.

D2 discloses that ixodid tick attachment cement and salivary gland cells contain similar immunoreactive polypeptides. A 90 kDd tick salivary gland polypeptide is conserved among ixodid tick genera and is a cement component (see abstract).

D3 discloses a 90 kDa tick salivary gland polypeptide that is a cement component. The protein was isolated from ixodid ticks, in particular from *Rhipicephalus appendiculatus*. Utilizing Western blots and immunocytochemistry, the 90 kDa protein was shown to be present in the glands and cement of several ixodid tick genera (p. 339, summary).

D8 describes the characterization of ixodid tick salivary-gland gene products, using recombinant DNA technology. Expression libraries from mRNA of salivary glands were made to produce the genes coding for them. 10 positive clones were detected using polyspecific antiserum. Immunoblots of salivary glands revealed the presence of several prominent polypeptides (90 and 45 kDa) when probed with the same rabbit antiserum that was used to screen the expression library. D8 describes the use of salivary-gland genes for characterizing secretory products which facilitate attachment to the host (cement) and maintain the lesion during the lengthy feeding interval (see abstract). D8 discloses also that cement collected from different tick species had similar polypeptide patterns with 13-15 polypeptides visible in minigels (p. 306, results and figure 1A, lanes 1 and 2). A 90 kDa tick salivary gland polypeptide was found to be a cement component (p. 307, discussion).

As illustrated by D2, D3 or D8, the concept of tissue cement proteins from blood-feeding parasites, in particular from ixodid ticks, was known in the prior art. Therefore, this single general concept is not acceptable, making it necessary to reconsider the technical relationship or interaction between the different sequences mentioned in the application. This will lead to their regrouping under different subjects, that is to say, each specific sequence falls under its own inventive concept, being a solution to the problem in a way that differs from the

state of the art. Therefore, the present application lacks unity within the meaning of Rule 13 PCT.

The separate inventions/groups of invention will be examined separately.

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. **Novelty: Article 33(2) PCT**

D1 discloses expressed sequenced tags and new genes from the cattle tick, Boophilus microplus.

D2, D3 and D8 disclose tissue cement proteins from blood-feeding parasites, in particular from ixodid ticks (see paragraph IV above).

Therefore, the subject-matter of claims 1-40, partially, (invention # 8, namely, the subject-matter of claims 1-40 that is directed to related tissue cement proteins from blood-feeding parasites, and functional equivalents thereof) is not considered new in the sense of Article 33(2) PCT.

The IPEA is of the opinion that the proteins disclosed in D2, D3 and D8 are "functional equivalents" of the tissue cement proteins of the present application. Therefore, the subject-matter of claims 1-40, partially, (inventions # 1-8, **with respect to "functional equivalents"** of the specific tissue cement proteins) is not considered new in the sense of Article 33(2) PCT.

The amino acid sequences of tissue cement proteins disclosed in the present application have not been made available to the public by any of the available prior art documents. D1 discloses an amino acid sequence of a cattle tick protein, however, the function of said protein is not described. D2, D3 and D8 describe tissue cement proteins from ticks, in particular a 90 kDa tick salivary gland polypeptide that was found to be a cement component. The prior art does not provide any genetic information for characterizing the salivary gland proteins or

genes that code for them. The prior art describes the use of tick attachment cement as the source of antigen for attempts to elicit tick feeding resistance (see D4), however, the use of tick tissue cement proteins for therapy, as a pharmaceutical or in the temporary or permanent bonding of tissues is not disclosed in the prior art. Therefore, the subject-matter of claims 1-40, partially, has not been made available to the public by any of the available prior art documents and cannot be derived from the available prior art in an obvious manner and therefore complies with the requirements of Articles 33(2) and (3) PCT .

Re Item VIII

Certain observations on the international application

1) **Clarity: Article 6 PCT**

The term "functional equivalent thereof" used in claim 8 is vague and unclear and leaves the reader in doubt as to the meaning of the technical features to which it refers, thereby rendering the definition of the subject-matter of said claim unclear (Article 6 PCT) as well as not novel (see paragraph V above).

Claims 2 and 3 are not clear. As is stated in Rule 6 (2a) PCT, claims shall not, except where absolutely necessary, rely, in respect of the technical features of the invention, on references to the description or drawings. In particular, they shall not rely on such references as: "as described in part...of the description". The terms "group A subtype" and "group A subtype" should be defined in the claims.

2) Claims 24, 26, 28-29 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

For the assessment of the present claims 24, 26, 28-29 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the

subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

United States Patent and Trademark Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 21 July 1999 (21.07.99)	
International application No. PCT/GB98/03397	**Applicant's or agent's file reference**
International filing date (day/month/year) 12 November 1998 (12.11.98)	**Priority date** (day/month/year) 12 November 1997 (12.11.97)
Applicant PAESEN, Guido, Christian et al	

1. The designated Office is hereby notified of its election made:

   [X] in the demand filed with the International Preliminary Examining Authority on:

   04 June 1999 (04.06.99)

   [ ] in a notice effecting later election filed with the International Bureau on:

   _____

2. The election [X] was

   [ ] was not

   made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

S. Mafla

Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF THE RECORDING OF A CHANGE

(PCT Rule 92bis.1 and Administrative Instructions, Section 422)

To:

MERCER, Christopher, Paul
Carpmaels & Ransford
43 Bloomsbury Square
London WC1A 2RA
ROYAUME-UNI

Date of mailing (day/month/year)
26 April 2000 (26.04.00)

Applicant's or agent's file reference

IMPORTANT NOTIFICATION

International application No.
PCT/GB98/03397

International filing date (day/month/year)
12 November 1998 (12.11.98)

1. The following indications appeared on record concerning:

[X] the applicant [ ] the inventor [ ] the agent [ ] the common representative

Name and Address
NATIONAL ENVIRONMENTAL RESEARCH COUNCIL
Polaris House
North Star Avenue
Swindon SN2 1EU
United Kingdom

State of Nationality: GB
State of Residence: GB
Telephone No.:
Facsimile No.:
Teleprinter No.:

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

[ ] the person [X] the name [ ] the address [ ] the nationality [ ] the residence

Name and Address
NATURAL ENVIRONMENTAL RESEARCH COUNCIL
Polaris House
North Star Avenue
Swindon SN2 1EU
United Kingdom

State of Nationality: GB
State of Residence: GB
Telephone No.:
Facsimile No.:
Teleprinter No.:

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

[X] the receiving Office
[ ] the International Searching Authority
[ ] the International Preliminary Examining Authority
[ ] the designated Offices concerned
[X] the elected Offices concerned
[ ] other:

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland
Facsimile No.: (41-22) 740.14.35

Authorized officer
I. Britel
Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF THE RECORDING OF A CHANGE

(PCT Rule 92bis.1 and Administrative Instructions, Section 422)

To:

MERCER, Christopher, Paul
Carpmaels & Ransford
43 Bloomsbury Square
London WC1A 2RA
ROYAUME-UNI

Date of mailing (day/month/year) 26 April 2000 (26.04.00)	
Applicant's or agent's file reference	IMPORTANT NOTIFICATION
International application No. PCT/GB98/03397	International filing date (day/month/year) 12 November 1998 (12.11.98)

1. The following indications appeared on record concerning:

[X] the applicant [ ] the inventor [ ] the agent [ ] the common representative

Name and Address	State of Nationality	State of Residence
NATIONAL ENVIRONMENTAL RESEARCH COUNCIL Polaris House North Star Avenue Swindon SN2 1EU United Kingdom	GB	GB
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

[ ] the person [X] the name [ ] the address [ ] the nationality [ ] the residence

Name and Address	State of Nationality	State of Residence
NATURAL ENVIRONMENTAL RESEARCH COUNCIL Polaris House North Star Avenue Swindon SN2 1EU United Kingdom	GB	GB
	Telephone No	
	Facsimile No.	
	Teleprinter No.	

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

[X] the receiving Office
[ ] the International Searching Authority
[ ] the International Preliminary Examining Authority
[ ] the designated Offices concerned
[X] the elected Offices concerned
[ ] other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer I. Britel
Facsimile No.: (41-22) 740.14.35	Telephone No : (41-22) 338.83.38

Form PCT/IB/306 (March 1994) 003245125

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

by fax and post

PCT

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL PRELIMINARY
EXAMINATION REPORT
(PCT Rule 71.1)

To:

MERCER, Christopher Paul
CARPMAELS & RANSFORD
43 Bloomsbury Square
London WC1A 2RA
GRANDE BRETAGNE

Fax: 0171 4054 166

Date of mailing *(day/month/year)* 14.03.00

Applicant's or agent's file reference
P018303WO

IMPORTANT NOTIFICATION

International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/GB98/03397	12/11/1998	12/11/1997

Applicant
NATIONAL ENVIRONMENTAL RESEARCH COUNCIL et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.

2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.

3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/

European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized officer

Vullo, C

Tel.+49 89 2399-8061

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
P018303WO		
International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/GB98/03397	12/11/1998	12/11/1997
International Patent Classification (IPC) or national classification and IPC C12N15/12		
Applicant NATIONAL ENVIRONMENTAL RESEARCH COUNCIL et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 9 sheets, including this cover sheet.

   ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

   - I ☒ Basis of the report
   - II ☐ Priority
   - III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
   - IV ☒ Lack of unity of invention
   - V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations suporting such statement
   - VI ☐ Certain documents cited
   - VII ☐ Certain defects in the international application
   - VIII ☒ Certain observations on the international application

Date of submission of the demand	Date of completion of this report
14/06/1999	14.03.00
Name and mailing address of the international preliminary examining authority: European Patent Office D-80298 Munich Tel: +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Paresce, D Telephone No. +49 89 2399 8995

Form PCT/IPEA/409 (cover sheet) (January 1994)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB98/03397

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-34 as originally filed

Claims, No.:

1-40 as originally filed

Drawings, sheets:

1/19-19/19 as originally filed

2. The amendments have resulted in the cancellation of:

☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:

☐ restricted the claims.

☒ paid additional fees.

☐ paid additional fees under protest.

☐ neither restricted nor paid additional fees.

2. ☐ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is

   ☐ complied with.

   ☒ not complied with for the following reasons:

   see separate sheet

4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

   ☒ all parts.

   ☐ the parts relating to claims Nos. .

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-40, partially
	No:	Claims	1-40, partially
Inventive step (IS)	Yes:	Claims	1-40, partially
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-23, 25, 27, 30-40
	No:	Claims	

2. Citations and explanations

   see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

The documents mentioned in this communication are numbered as in the search report, i.e. D1 corresponds to the first document of the search report.

Re Item IV

Lack of unity of invention

The claims of present application relate to eight different inventions. The separate inventions/groups of invention are:

1) Claims 1-40, partially, are directed to a tissue cement protein having the amino acid sequence shown in Figure 3, as well as to functional equivalents of said tissue cement protein. The claims are further directed to said tissue cement protein that has been genetically or chemically fused to one or more peptides, pharmaceutical compositions comprising said tissue cement protein, as well as methods of use of said protein in therapy, as a vaccine, for bonding animal tissues, or for use as a protective immunogen in the control of diseases caused by infections transmitted by parasites. The claims are directed to a nucleic acid molecule which encodes said tissue cement protein, a nucleic acid molecule specifically hybridizing with said molecule, vectors comprising said nucleic acid molecule, host cells transformed with said molecule, a transgenic animal transformed with said molecule, and a method of preparing said tissue cement protein.

2) Claims 1-40, partially, are directed to a tissue cement protein having the amino acid sequence shown in Figure 7 and functional equivalents thereof. The claims are further directed to said tissue cement protein that has been genetically or chemically fused to one or more peptides, pharmaceutical compositions comprising said tissue cement protein, as well as methods of use of said protein in therapy, as a vaccine, for bonding animal tissues, or for use as a protective immunogen in the control of diseases caused by infections transmitted by parasites. The claims are directed to a nucleic acid molecule which encodes said tissue cement protein, a nucleic acid molecule specifically hybridizing with said molecule, vectors comprising said nucleic acid molecule, host cells transformed with said molecule, a transgenic animal transformed with said molecule, and a method of preparing said tissue cement protein.

3) Claims 1-40, partially, are directed to a tissue cement protein containing a partial amino acid sequence shown in Figure 2. The claims are further directed to pharmaceutical compositions comprising said tissue cement protein, and methods of use of said protein (see invention 1 above).

4) Claims 1-40, partially, are directed to a tissue cement protein containing a partial amino acid sequence shown in Figure 4. The claims are further directed to pharmaceutical compositions comprising said tissue cement protein, and methods of use of said protein (see invention 1 above).

5) Claims 1-40, partially, are directed to a tissue cement protein containing a partial amino acid sequence shown in Figure 5. The claims are further directed to pharmaceutical compositions comprising said tissue cement protein, and methods of use of said protein (see invention 1 above).

6) Claims 1-40, partially, are directed to a tissue cement protein containing a partial amino acid sequence shown in Figure 6. The claims are further directed to pharmaceutical compositions comprising said tissue cement protein, and methods of use of said protein (see invention 1 above).

7) Claims 1-40, partially, are directed to a tissue cement protein containing a partial amino acid sequence shown in Figure 8. The claims are further directed to pharmaceutical compositions comprising said tissue cement protein, and methods of use of said protein (see invention 1 above).

8) Claims 1-40, partially, are directed to related tissue cement proteins from blood-feeding parasites. The claims are further directed to pharmaceutical compositions comprising said tissue cement protein, and methods of use of said protein (see invention 1 above).

The separate inventions/groups of invention are not so linked as to form a single general **inventive** concept (Rule 13.1 PCT) for the following reasons:

The general concept underlying the eight above identified inventions of the present application can be seen as the provision of tissue cement proteins from

blood-feeding parasites, preferably ticks. However, this general concept is not considered novel having regard to the state of the art as illustrated by, for example, D2, D3, or D8.

D2 discloses that ixodid tick attachment cement and salivary gland cells contain similar immunoreactive polypeptides. A 90 kDd tick salivary gland polypeptide is conserved among ixodid tick genera and is a cement component (see abstract).

D3 discloses a 90 kDa tick salivary gland polypeptide that is a cement component. The protein was isolated from ixodid ticks, in particular from *Rhipicephalus appendiculatus*. Utilizing Western blots and immunocytochemistry, the 90 kDa protein was shown to be present in the glands and cement of several ixodid tick genera (p. 339, summary).

D8 describes the characterization of ixodid tick salivary-gland gene products, using recombinant DNA technology. Expression libraries from mRNA of salivary glands were made to produce the genes coding for them. 10 positive clones were detected using polyspecific antiserum. Immunoblots of salivary glands revealed the presence of several prominent polypeptides (90 and 45 kDa) when probed with the same rabbit antiserum that was used to screen the expression library. D8 describes the use of salivary-gland genes for characterizing secretory products which facilitate attachment to the host (cement) and maintain the lesion during the lengthy feeding interval (see abstract). D8 discloses also that cement collected from different tick species had similar polypeptide patterns with 13-15 polypeptides visible in minigels (p. 306, results and figure 1A, lanes 1 and 2). A 90 kDa tick salivary gland polypeptide was found to be a cement component (p. 307, discussion).

As illustrated by D2, D3 or D8, the concept of tissue cement proteins from blood-feeding parasites, in particular from ixodid ticks, was known in the prior art. Therefore, this single general concept is not acceptable, making it necessary to reconsider the technical relationship or interaction between the different sequences mentioned in the application. This will lead to their regrouping under different subjects, that is to say, each specific sequence falls under its own inventive concept, being a solution to the problem in a way that differs from the

state of the art. Therefore, the present application lacks unity within the meaning of Rule 13 PCT.

The separate inventions/groups of invention will be examined separately.

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. **Novelty: Article 33(2) PCT**

D1 discloses expressed sequenced tags and new genes from the cattle tick, Boophilus microplus.

D2, D3 and D8 disclose tissue cement proteins from blood-feeding parasites, in particular from ixodid ticks (see paragraph IV above).

Therefore, the subject-matter of claims 1-40, partially, (invention # 8, namely, the subject-matter of claims 1-40 that is directed to related tissue cement proteins from blood-feeding parasites, and functional equivalents thereof) is not considered new in the sense of Article 33(2) PCT.

The IPEA is of the opinion that the proteins disclosed in D2, D3 and D8 are "functional equivalents" of the tissue cement proteins of the present application. Therefore, the subject-matter of claims 1-40, partially, (inventions # 1-8, **with respect to "functional equivalents"** of the specific tissue cement proteins) is not considered new in the sense of Article 33(2) PCT.

The amino acid sequences of tissue cement proteins disclosed in the present application have not been made available to the public by any of the available prior art documents. D1 discloses an amino acid sequence of a cattle tick protein, however, the function of said protein is not described. D2, D3 and D8 describe tissue cement proteins from ticks, in particular a 90 kDa tick salivary gland polypeptide that was found to be a cement component. The prior art does not provide any genetic information for characterizing the salivary gland proteins or

genes that code for them. The prior art describes the use of tick attachment cement as the source of antigen for attempts to elicit tick feeding resistance (see D4), however, the use of tick tissue cement proteins for therapy, as a pharmaceutical or in the temporary or permanent bonding of tissues is not disclosed in the prior art. Therefore, the subject-matter of claims 1-40, partially, has not been made available to the public by any of the available prior art documents and cannot be derived from the available prior art in an obvious manner and therefore complies with the requirements of Articles 33(2) and (3) PCT .

Re Item VIII

Certain observations on the international application

1) **Clarity: Article 6 PCT**

The term "functional equivalent thereof" used in claim 8 is vague and unclear and leaves the reader in doubt as to the meaning of the technical features to which it refers, thereby rendering the definition of the subject-matter of said claim unclear (Article 6 PCT) as well as not novel (see paragraph V above).

Claims 2 and 3 are not clear. As is stated in Rule 6 (2a) PCT, claims shall not, except where absolutely necessary, rely, in respect of the technical features of the invention, on references to the description or drawings. In particular, they shall not rely on such references as: "as described in part...of the description". The terms "group A subtype" and "group A subtype" should be defined in the claims.

2) Claims 24, 26, 28-29 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

For the assessment of the present claims 24, 26, 28-29 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the

subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

PATENT COOPERATION TREATY

DE 17 2 00

by fax and post

From the:
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:
MERCER, Christopher Paul
CARPMAELS & RANSFORD
43 Bloomsbury Square
London WC1A 2RA
GRANDE BRETAGNE

2HRG

Fax 0171 405 4166

RECEIVED
17 JAN 2000
2MS

PCT

WRITTEN OPINION

(PCT Rule 66)

Date of mailing *(day/month/year)*	17. 01. 00
Applicant's or agent's file reference: P018303WO	REPLY DUE: within 1 month(s) from the above date of mailing
International application No.: PCT/GB98/03397	International filing date *(day/month/year)*: 12/11/1998
Priority date *(day/month/year)*: 12/11/1997	
International Patent Classification (IPC) or both national classification and IPC: C12N15/12	
Applicant: NATIONAL ENVIRONMENTAL RESEARCH COUNCIL et al.	

1. This written opinion is the **first** drawn up by this International Preliminary Examining Authority.

2. This opinion contains indications relating to the following items:

- I ☒ Basis of the opinion
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☒ Lack of unity of invention
- V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain document cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

3. The applicant is hereby **invited to reply** to this opinion.

When? See the time limit indicated above. The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d).

How? By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

Also: For an additional opportunity to submit amendments, see Rule 66.4.
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis.
For an informal communication with the examiner, see Rule 66.6.

If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.

4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: 12/03/2000.

Name and mailing address of the international preliminary examining authority:
European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized officer / Examiner
Paresce, D

Formalities officer (incl. extension of time limits)
Vullo, C
Telephone No. +49 89 2399 8061

WRITTEN OPINION

International application No. PCT/GB98/03397

I. Basis of the opinion

1. This opinion has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed".*):

Description, pages:

1-34 as originally filed

Claims, No.:

1-40 as originally filed

Drawings, sheets:

1/19-19/19 as originally filed

2. The amendments have resulted in the cancellation of:

☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. This opinion has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

IV. Lack of unity of invention

1. In response to the invitation (Form PCT/IPEA/405) to restrict or pay additional fees, the applicant has:

☐ restricted the claims.

☒ paid additional fees.

☐ paid additional fees under protest.

☐ neither restricted nor paid additional fees.

2. ☐ This Authority found that the requirement of unity of invention is not complied with for the following reasons

WRITTEN OPINION

and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees:

3. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this opinion:

   ☒ all parts.

   ☐ the parts relating to claims Nos. .

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	1-40 partially
Inventive step (IS)	Claims	
Industrial applicability (IA)	Claims	

2. Citations and explanations

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

WRITTEN OPINION
SEPARATE SHEET

International application No. PCT/GB98/03397

Re Item I

Basis of the opinion

The claims of present application relate to eight different inventions. The separate inventions/groups of invention are:

1) Claims 1-40, partially, are directed to a tissue cement protein having the amino acid sequence shown in Figure 3, as well as to functional equivalents of said tissue cement protein. The claims are further directed to said tissue cement protein that has been genetically or chemically fused to one or more peptides, pharmaceutical compositions comprising said tissue cement protein, as well as methods of use of said protein in therapy, as a vaccine, for bonding animal tissues, or for use as a protective immunogen in the control of diseases caused by infections transmitted by parasites. The claims are directed to a nucleic acid molecule which encodes said tissue cement protein, a nucleic acid molecule specifically hybridizing with said molecule, vectors comprising said nucleic acid molecule, host cells transformed with said molecule, a transgenic animal transformed with said molecule, and a method of preparing said tissue cement protein.

2) Claims 1-40, partially, are directed to a tissue cement protein having the amino acid sequence shown in Figure 7 and functional equivalents thereof. The claims are further directed to said tissue cement protein that has been genetically or chemically fused to one or more peptides, pharmaceutical compositions comprising said tissue cement protein, as well as methods of use of said protein in therapy, as a vaccine, for bonding animal tissues, or for use as a protective immunogen in the control of diseases caused by infections transmitted by parasites. The claims are directed to a nucleic acid molecule which encodes said tissue cement protein, a nucleic acid molecule specifically hybridizing with said molecule, vectors comprising said nucleic acid molecule, host cells transformed with said molecule, a transgenic animal transformed with said molecule, and a method of preparing said tissue cement protein.

3) Claims 1-40, partially, are directed to a tissue cement protein containing a partial amino acid sequence shown in Figure 2. The claims are further directed to

pharmaceutical compositions comprising said tissue cement protein, and methods of use of said protein (see invention 1 above).

4) Claims 1-40, partially, are directed to a tissue cement protein containing a partial amino acid sequence shown in Figure 4. The claims are further directed to pharmaceutical compositions comprising said tissue cement protein, and methods of use of said protein (see invention 1 above).

5) Claims 1-40, partially, are directed to a tissue cement protein containing a partial amino acid sequence shown in Figure 5. The claims are further directed to pharmaceutical compositions comprising said tissue cement protein, and methods of use of said protein (see invention 1 above).

6) Claims 1-40, partially, are directed to a tissue cement protein containing a partial amino acid sequence shown in Figure 6. The claims are further directed to pharmaceutical compositions comprising said tissue cement protein, and methods of use of said protein (see invention 1 above).

7) Claims 1-40, partially, are directed to a tissue cement protein containing a partial amino acid sequence shown in Figure 8. The claims are further directed to pharmaceutical compositions comprising said tissue cement protein, and methods of use of said protein (see invention 1 above).

8) Claims 1-40, partially, are directed to related tissue cement proteins from blood-feeding parasites. The claims are further directed to pharmaceutical compositions comprising said tissue cement protein, and methods of use of said protein (see invention 1 above).

The separate inventions/groups of invention will be examined separately.

Re Item V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

The documents mentioned in this communication are numbered as in the search report, i.e. D1 corresponds to the first document of the search report.

1. **Novelty: Article 33(2) PCT**

D1 discloses expressed sequenced tags and new genes from the cattle tick, Boophilus microplus.

D2 discloses that ixodid tick attachment cement and salivary gland cells contain similar immunoreactive polypeptides. A 90 kDd tick salivary gland polypeptide is conserved among ixodid tick genera and is a cement component (see abstract).

D3 discloses a 90 kDa tick salivary gland polypeptide that is a cement component. The protein was isolated from ixodid ticks, in particular from Rhipicephalus appendiculatus. Utilizing Western blots and immunocytochemistry, the 90 kDa protein was shown to be present in the glands and cement of several ixodid tick genera (p. 339, summary).

D8 describes the characterization of ixodid tick salivary-gland gene products, using recombinant DNA technology. Expression libraries from mRNA of salivary glands were made to produce the genes coding for them. 10 positive clones were detected using polyspecific antiserum. Immunoblots of salivary glands revealed the presence of several prominent polypeptides (90 and 45 kDa) when probed with the same rabbit antiserum that was used to screen the expression library. D8 describes the use of salivary-gland genes for characterizing secretory products which facilitate attachment to the host (cement) and maintain the lesion during the lengthy feeding interval (see abstract). D8 discloses also that cement collected from different tick species had similar polypeptide patterns with 13-15 polypeptides visible in minigels (p. 306, results and figure 1A, lanes 1 and 2). A 90 kDa tick salivary gland polypeptide was found to be a cement component (p. 307, discussion).

D2, D3 and D8 disclose tissue cement proteins from blood-feeding parasites, in particular from ixodid ticks.

Therefore, the subject-matter of claims 1-40, partially, (invention # 8, namely, the subject-matter of claims 1-40 that is directed to related tissue cement proteins from blood-feeding parasites, and functional equivalents thereof) is not considered new in the sense of Article 33(2) PCT.

The IPEA is of the opinion that the proteins disclosed in D1, D2 and D3 are "functional equivalents" of the tissue cement proteins of the present application. Therefore, the subject-matter of claims 1-40, partially, (inventions # 1-8, **with respect to "functional equivalents"** of the specific tissue cement proteins) is not considered new in the sense of Article 33(2) PCT.

Re Item VIII

Certain observations on the international application

1) **Clarity: Article 6 PCT**

The term "functional equivalent thereof" used in claim 8 is vague and unclear and leaves the reader in doubt as to the meaning of the technical features to which it refers, thereby rendering the definition of the subject-matter of said claim unclear (Article 6 PCT) as well as not novel (see paragraph V above).

Claims 2 and 3 are not clear. As is stated in Rule 6 (2a) PCT, claims shall not, except where absolutely necessary, rely, in respect of the technical features of the invention, on references to the description or drawings. In particular, they shall not rely on such references as: "as described in part...of the description". The terms "group A subtype" and "group A subtype" should be defined in the claims.

2) Claims 24, 26, 28-29 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

For the assessment of the present claims 24, 26, 28-29 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the

claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

3) Should the applicant file a new set of claims, which take account of the above comments, he is requested to clearly identify the amendments carried out, no matter whether they concern amendments by addition, replacement or deletion, and to indicate the passages of the application as filed on which these amendments are based (see Rule 66.8(a) PCT), to facilitate the examination of the conformity of the amended application with the requirements of Article 34(2)(b) PCT. If the applicant regards it as appropriate these indications could be submitted in handwritten form on a copy of the relevant parts of the application as filed. The attention of the Applicant is drawn to the fact that the application may not be amended in such a way that it contains subject-matter which extends beyond the content of the application as filed, Article 34(2)(b) PCT.

PATENT COOPERATION TREATY

HRS

From the INTERNATIONAL SEARCHING AUTHORITY

PCT PA/303/NO

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION

(PCT Rule 44.1)

To:
CARPMAELS & RANSFORD
Attn. MERCER, C.
43 Bloomsbury Square
London WC1A 2RA
UNITED KINGDOM

	Date of mailing *(day/month/year)* 05/03/1999
Applicant's or agent's file reference	**FOR FURTHER ACTION** See paragraphs 1 and 4 below
International application No. PCT/GB 98/03397	International filing date *(day/month/year)* 12/11/1998

Applicant

NATIONAL ENVIRONMENTAL RESEARCH COUNCIL et al.

1. [X] The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

Filing of amendments and statement under Article 19:
The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland
Fascimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. [ ] The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. [ ] **With regard to the protest** against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

[ ] the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

[ ] no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90*bis*.1 and 90*bis*.3, respectively, before the completion of the technical preparations for international publication.

Within **19 months** from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within **20 months** from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Mireille Claudepierre

Form PCT/ISA/220 (July 1998)

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international pbulication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

NOTES TO FORM PCT/ISA/220 (contin

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped),whether

(i) the claim is unchanged;

(ii) the claim is cancelled;

(iii) the claim is new;

(iv) the claim replaces one or more claims as filed;

(v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."

2. [Where originally there were 15 claims and after amendment of all claims there are 11]:
"Claims 1 to 15 replaced by amended claims 1 to 11."

3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."

4. [Where various kinds of amendments are made]:
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international appplication is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	**FOR FURTHER ACTION** see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/GB 98/ 03397	International filing date *(day/month/year)* 12/11/1998	(Earliest) Priority Date *(day/month/year)* 12/11/1997
Applicant NATIONAL ENVIRONMENTAL RESEARCH COUNCIL et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.

[X] It is also accompanied by a copy of each prior art document cited in this report.

1. **Basis of the report**

   a. With regard to the **language,** the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

   [ ] the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

   b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

   [X] contained in the international application in written form.

   [ ] filed together with the international application in computer readable form.

   [X] furnished subsequently to this Authority in written form.

   [ ] furnished subsequently to this Authority in computer readble form.

   [ ] the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

   [ ] the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. [X] **Certain claims were found unsearchable** (See Box I).

3. [ ] **Unity of invention is lacking** (see Box II).

4. With regard to the **title,**

   [ ] the text is approved as submitted by the applicant.

   [X] the text has been established by this Authority to read as follows:

   TISSUE CEMENT PROTEINS FROM RHIPICEPHALUS APPENDICULATUS

5. With regard to the **abstract,**

   [X] the text is approved as submitted by the applicant.

   [ ] the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No. _____

   [ ] as suggested by the applicant.

   [ ] because the applicant failed to suggest a figure.

   [ ] because this figure better characterizes the invention.

   [X] None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 98/03397

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 28, 29 and 24, 26 (as far as in vivo methods are concerned) are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 98/03397

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/12 C12N15/86 C12N15/62 C12N5/10 C07K14/435
A61K38/17 A61K39/00 A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N C07K A61K A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	A.L. CRAMPTON ET AL.: "Expression sequenced tags and new genes from the cattle tick, Boophilus microplus" EMBL SEQUENCE DTABASE,11 September 1997, XP002093748 Heidelberg, FRG Boophilus microplus EST 198 putative nuclear antigen mRNA sequence; Accession no. U92768; & EXP. APPL. ACAROL. , vol. 22, no. 3, 1998, pages 177-186, --- -/--	1

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
19 February 1999	05/03/1999

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Hornig, H

2

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
A	D.C. JAWORSKI ET AL.: "Tick (Acari: Ixodidae) attachement cement and salvary gland cells contain similar immunoreactive polypeptides" JOURNAL OF MEDICAL ENTOMOLOGY, vol. 29, no. 2, March 1992, pages 305-309, XP002093749 Published by The Entomological Society of America, Lanham, Maryland, US cited in the application see the whole document ---	1-40
A	D.C. JAWORSKI ET AL.: "Evidence that a 90 kDa tick salivary galnd polypeptide is a cement protein" F.DUSBÁBEK AND V. BUKVA (EDS.): MODERN ACAROLOGY, ACADEMIA PRAGUE, vol. 1, 1991, pages 335-340, XP002094114 SPB Academic Publishing bv, The Hague, NL Modern Acarology Volume I. Proceedings of the VIII International Congress of Acarology, Held in Ceske Budejovice, Czechoslovakia, 6-11 August 1990; see the whole document ---	1-40
A	S. SHAPIRO ET AL.: "Acquired resistance to Ixodid Ticks induced by Tixk cement antigen" EXPERIMENTAL & APPLIED ACAROLOGY, vol. 7, 1989, pages 33-41, XP002093750 Elsevier Science Publishers B.V., Amsterdam, NL cited in the application see the whole document ---	1-40
A	S.Z. SHAPIRO ET AL.: "Tick antigens recognized by serum from a guinea pig resistant to infestation with the tick Rhipicephalus appendiculatus" J. PARASITOLOGY, vol. 72, no. 3, June 1986, pages 454-463, XP002093751 see the whole document ---	1-40
A	WANG H ET AL: "COMPARISON OF THE PROTEINS IN SALIVARY GLANDS, SALIVA AND HAEMOLYMPH OF RHIPICEPHALUS APPENDICULATUS FEMALE TICKS DURING FEEDING" PARASITOLOGY, vol. 109, no. 4, November 1994, pages 517-523, XP002050816 see the whole document ---	1-40

-/--

2

International Application No
PCT/GB 98/03397

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
A	S.J. BROWN AND P.W. ASKENASE: "Amblyomma americanum: Physicochemical Isolation of a protein derived from the ick slivary gland that is capable of inducing immune resistance in guinea pigs" EXPERIMENTAL PARASITOLOGY, vol. 62, no. 1, August 1986, pages 40-50, XP002093752 NEW YORK, US cited in the application see the whole document	1-40
A	G.R. NEEDHAM ET AL.: "Characterization of Ixodid Tick salivary-gland gene products, using recombinant DNA technology" EXPERIMENTAL & APPLIED ACAROLOGY, vol. 7, 1989, pages 21-32, XP002093753 Elsevier Science Publishers, B.V., Amsterdam, NL cited in the application see the whole document	1-40
A	GB 2 142 334 A (INT CENTRE OF INSECT PHYSIOLOG) 16 January 1985 see the whole document	1-40

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
T/GB 98/03397

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2142334 A	16-01-1985	NONE	